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Primary lymphoma of bone is a rare disease, first described by Oberling in 1928 as reticulum 
cell sarcoma of bone.1 He accomplished a reliable and consistent separation of reticulum 
cell sarcoma of bone from Ewing’s sarcoma, a histomorphological mimic. Reticulin fibers 
surrounding individual tumor cells are a characteristic finding in primary lymphoma of bone, 
hence the original terminology of reticulum cell sarcoma. It was not until 1939 that Parker 
and Jackson described 17 cases of so-called ‘primary reticulum cell sarcoma of bone’ and 
established this disease as a distinct and accepted clinical entity.2 In 1963 Ivins and later in 1974 
Boston et al. recognized the lymphoid origin of the tumor and named it malignant lymphoma 
of bone.3, 4 In 1987 Vassallo introduced  the use of immunohistochemistry to characterize the 
true cellular origin of these tumors.5 Even today the histopathological diagnosis of primary 
lymphoma of bone can be challenging, it is often only with the help of lymphoma cell specific 
immunohistochemical markers that difficult cases can be diagnosed in a reliable manner. 
The subtype of lymphoma that is most often diagnosed in these cases is diffuse large B cell 
lymphoma. In this thesis we focus on primary diffuse large B cell lymphoma of bone. Other 
subtypes, such as primary follicular lymphoma of bone, primary Hodgkin lymphoma of bone, 
primary T cell lymphoma of bone or acute anaplastic large cell lymphoma in children do occur 
on rare occasions, but these subtypes were excluded in our studies.  
Since 1974, when Boston gave primary lymphoma of bone its current name, multiple different 
systems of classification of non-Hodgkin lymphoma have been used. This has complicated 
research, as consensus on definitions and terminology is essential for both clinical practice 
and investigation. Poor reproducibility of morphologic criteria have helped to switch from the 
Kiel and Lukes-Collins classification via the Working Formulation system in 1982 to the REAL 
classification in 1994. From the REAL classification, in 2001 the World Health Organization 
(WHO) classification system was established. This classification system is used internationally 
nowadays. The diagnosis and classification of non-Hodgkin lymphoma has moved from a 
purely morphologically driven classification system then, into one in which a wide range of 
information, including immunophenotype and molecular genetic features, are part of the 
disease definitions today. In the WHO classification, primary diffuse large B cell lymphoma of 
bone is defined as a mono-ostotic disease with or without involvement of regional lymph nodes, 
or as a poly-ostotic disease affecting multiple skeletal sites without visceral- or lymph node 
involvement.6 The percentage of primary diffuse large B cell lymphoma of bone is only 5% of 
all extranodal non-Hodgkin lymphomas and is less than 1% of all non-Hodgkin lymphomas.6-8 
As a consequence of this low incidence, scientific studies on this subject are uncommon. 
In 1953, the Netherlands Committee on Bone Tumors was founded in Leiden. This Commission 
keeps a large national registry of bone tumors in the Netherlands containing more than 25.000 
cases, including clinical data at presentation, histological slides of the tumor and complete 
radiographic documentation. This registry gave us the unique opportunity to assemble a 
large cohort of patients with primary diffuse large B cell lymphoma of bone, one of the largest 
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worldwide. Starting with this cohort, we initiated our research project on primary diffuse large 
B cell lymphoma of bone to increase the knowledge of this rare and poorly understood subtype 
of non-Hodgkin lymphoma.
Clinico-pathological characteristics
Primary diffuse large B cell lymphoma of bone often presents with pain or a palpable mass, 
most frequently in the long bones, especially the distal femur or the distal humerus. The 
median age at presentation is in the fifth decade, with male patients affected more often than 
female patients with a ratio of 1.8 : 1. Morphologically, almost all tumors are composed of large 
centroblast-like cells, often with multilobated nuclear features, but accurate morphological 
subclassification can be problematic due to mechanical crush, decalcification procedures 
or small sample size.8, 9 In many cases the pathologic features of the tumor, often including 
intralesional fibrosis and prominent tumor cell spindling, make the histopathologic diagnosis 
even more complicated. In inexperienced hands misdiagnoses do occur, often classifying the 
tumor as a primary bone sarcoma. 
Since 1971, the Ann Arbor system is used internationally for the staging of all Hodgkin and 
non-Hodgkin lymphomas (see table 1). 10 Although originally developed for staging patients 
with Hodgkin lymphoma, the Ann Arbor staging system provides the basis for anatomic staging 
in non-Hodgkin lymphomas as well. However, in non-Hodgkin lymphoma the Ann Arbor 
staging system has less prognostic value than in Hodgkin lymphoma.11 The Ann Arbor staging 
system was not designed to take into account the different pattern of disease seen in the non-
Hodgkin lymphomas, for example the often extranodal presentation.12 It neither takes into 
account the grade of the tumor, which is prognostically relevant in non-Hodgkin lymphoma. 
Primary diffuse large B cell lymphoma of bone most often presents at one bone localization, 
which is classified as stage I. The stages II and III are rarely applicable in primary diffuse large B 
cell lymphoma of bone. In our studies, all stage IV cases had multiple bone localizations, none 
had bone marrow involvement. To avoid these staging problems for extranodal lymphoma, 
several authors choose to include only stage I patients in their bone lymphoma studies, which 
may lead to an imperfect representation of patients in literature.
Historically, a wide variety of therapies for primary diffuse large B cell lymphoma of bone has been 
used, including radiotherapy, surgery (amputation) and chemotherapy. For about twenty-five years 
most primary diffuse large B cell lymphoma of bone patients have been treated with a combination of 
radiotherapy and CHOP or CHOP-like chemotherapy. Probably the most important improvement 
for lymphoma patients in the last decade has been the addition of rituximab, a monoclonal 
antibody that specifically targets the CD20 positive B-cell, to the standard multiagent therapy 
regimen.13 However, data on primary diffuse large B cell lymphoma of bone patients treated with 
this regimen are still scarce.14 The five-year overall survival rate for primary diffuse large B cell 
lymphoma of bone is generally favorable compared to other intermediate grade, extranodal diffuse 
large B cell lymphoma, with a 5-years overall survival of 75% for the whole cohort in our studies 
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(see table 2).9, 15 16-18  Despite the improvement in diffuse large B cell lymphoma treatment with 
the addition of rituximab to CHOP, one quarter to one third of patients still die of their disease. 
The development of novel treatment regimens such as new anti-CD20 antibodies, proteasome 
inhibitors or lenalidomide are promising, but will require further study.19-21
Risk stratification in diffuse large B cell lymphoma
Diffuse large B cell lymphoma, including its extranodal subtype primary diffuse large B cell 
lymphoma of bone, represents a heterogeneous group of B-cell neoplasms, both clinically and 
morphologically. Paradoxically, the chemotherapy treatment regime for all of these patients 
is almost always the same: CHOP or CHOP-like chemotherapy, since 2001 in combination 
with rituximab. Strategies to intensify chemotherapy regimes, including autologous stem 
cell transplantation, have showed mixed results.22, 23 Intensive chemotherapy plus autologous 
stem cell transplantation might be beneficial for a selected group of high risk young patients, 
but which subgroup will benefit the most is unclear. Clinicians have difficulties defining the 
optimal treatment regimen for their diffuse large B cell lymphoma patients, because it is 
impossible to accurately predict response to standard treatment regimens. Patients present 
with apparently similar diagnoses, but have markedly different clinical outcomes, with a five 
year overall survival ranging from about 20% to 80% (see table 2). To identify patients who 
will show progressive disease despite standard chemotherapy and who will benefit from more 
intensive or different treatment modalities, numerous studies have been undertaken to design 
risk stratifications and to define meaningful prognostic markers. 
Clinical prognostic factors:
For risk stratification purposes lymphomas are traditionally divided into a group with primary 
tumor location in the lymph nodes and a group with primary extranodal presentation, which 
can occur at any site. It has long been held that overall survival for extranodal lymphomas as 
Table 1. Ann Arbor Staging Classification.
Stage I:  Involvement of a single lymph node region (I) or of a single extralymphatic organ or 
site. (IE)
Stage II:  Involvement of two or more lymph node regions on the same side of the diaphragm 
(II) or localized involvement of an extralymphatic organ or site and one or more lymph 
node regions on the same side of the diaphragm. (IIE)
Stage III:  Involvement of lymph node regions on both sides of the diaphragm (III), which may 
be accompanied by involvement of the spleen (IIIS) or by localized involvement of an 
extralymphatic organ or site (IIIE), or both. (IIISE)
Stage IV:  Diffuse or disseminated involvement of one or more extralymphatic organs or tissues 
with or without associated lymph node involvement.
The absence or presence of fever, night sweats, or unexplained loss of 10% or more of body weight 




a whole compares unfavorably with survival for nodal cases. Diffuse large B cell lymphoma of 
the testis and central nervous system for example - both lymphomas of immune-privileged 
sites - have been reported to have an unfavorable survival, with a 5-year overall survival 
below 50 %. In recent years, the survival of patients with lymphoma of immune-privileged 
sites has much improved, probably due to better diagnostic procedures and more tailored 
chemotherapy, including rituximab. 24-26 Primary diffuse large B cell lymphoma of bone has 
shown a much better survival, even in studies from more than ten years ago. It is therefore 
questionable whether this distinction between nodal lymphoma and extranodal lymphoma 
still holds its clinical relevance 27, 28 29, 30 (see table 2).
The recognition that the Ann Arbor anatomical staging system does not subdivide some types 
of non-Hodgkin lymphomas in a clinically useful way, and the recognition that other factors 
are important in predicting treatment outcome, has led to the development of the International 
Prognostic Index (IPI) in 1993. The IPI is based on a limited set of clinical and laboratory 
variables, which makes it a useful and affordable index in daily practice (see table 3). 43 44 
Since one parameter of the index is the number of extranodal sites and another parameter 
is the Ann Arbor stage, this index is not directly intended for indexing primary extranodal 
lymphomas. However, some studies indicate that the IPI is nonetheless applicable for staging 
primary extranodal lymphomas. 45 
Molecular genetic prognostic factors:
In the last decade, several molecular techniques, e.g. using DNA and RNA derived from 
tumor cells, have been developed to study the pathogenesis of diffuse large B cell lymphoma in 
more detail. However, it is important to realize that most studies using these new techniques 
concern nodal diffuse large B cell lymphoma, as those tissue samples are more abundantly 
available than tissue samples from extranodal lymphomas. Moreover, in contrast to extranodal 
lymphomas, cell lines of nodal diffuse large B-cell lymphoma are generally available, allowing 
for functional testing. These new techniques are also increasingly being used in extranodal 
lymphomas and future studies will be necessary to investigate to what extend the results of 
nodal diffuse large B-cell lymphoma can be extrapolated to extranodal lymphoma. 
Table 2. Overall 5 years survival (OS) in diffuse large B cell lymphoma
Primary location Reference 5 year OS %
nodal Sehn32, Gutierrez33 69-70
nodal (elderly patients) Feugier34, Coiffier35 58-60
testis Al-Abbadi36, Vitolo25, Mazloom26 60-86
central nervous system Shenkier37, Hattab38, Yamanaka39, Gavrilovic27 18-46
bone  Heyning10, Beal18, Ramadan19 62-88
stomach Leopardo40, Hung41, Zhang42 50-100
skin (primary cutaneous  Dijkman28, Grange43 25-41




Gene expression profiling can divide diffuse large B cell lymphoma into two histological 
indistinguishable molecular subtypes: a prognostically favorable group of germinal center 
B-cell (GCB) phenotype and a prognostically unfavorable group of activated B-cell (ABC or 
non-GC) phenotype.46 The GCB subtype has a significantly better outcome, 80% five year 
overall survival versus 45% five year overall survival for the ABC subtype, independent from 
IPI classification.47, 48 These two subtypes apparently arise from B-cells that are at separate 
stages of differentiation. Each subtype has a different process of malignant transformation 
and acquires distinct oncogenic abnormalities. In GCB phenotype lymphoma the germinal 
center B cells of the malignant clone continue to undergo somatic hypermutation. They avoid 
cell death by oncogenic translocations such as the t(14;18) translocation or TP53 mutations.49 
Anti-apoptotic pathways are activated by the overexpression of bcl-2 as a result of a t(14;18) 
resulting in a fusion of IgH promoter to BCL-2. However, the presence of this specific 
translocation does not have an inverse impact on prognosis. 50, 51 Secondary changes, such as 
TP53 mutations may occur in a subset of these patients. The overall survival is significantly 
worse for patients with TP53 mutations than for patients with wild type TP53 in GCB-type 
diffuse large B-cell lymphoma.49, 52 
Few studies exist on BCL-2 gene rearrangement in primary diffuse large B cell lymphoma of 
bone. Gianelli et al. found BCL-2/IgH rearrangement in 5% of cases, Bhagavathi in 4 of 21 
cases. 53, 54 No prognostic effect could be detected in these small cohorts (see table 4). 
As germinal-center B cells begin to differentiate into plasma cells, they upregulate interferon 
regulatory factor 4 (IRF4). This is the stage of differentiation where the malignant clone of 
ABC-type diffuse large B-cell lymphoma likely arises. The ABC subtype often carries a 
Table 3:. International Prognostic Index
One point is assigned for each of the following risk factors:
  Age greater than 60 years
  Stage III or IV disease
  Elevated serum LDH
  WHO performance status of 2 or more
  More than 1 extranodal site
The sum of the points allotted correlates with a median three-year survival ranging from 91% to 
59%.
Table 4. Gene rearrangements in primary diffuse large B cell lymphoma of bone patients
Gene(s) Reference Technique Rearrangements
IgH Bhagavathi55 PCR 10/17
IgH/BCL-2 Bhagavathi, Gianelli54 PCR 4/17, 2/41
 Bhagavathi FISH 4/21
BCL-2 Lima56 FISH 9/32
BCL-6 Bhagavathi FISH 3/21
C-MYC Bhagavathi, Lima FISH 2/21, 3/32
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homozygous deletion of the CDKN2A (INK4A-ARF) locus, which encodes p16, an inhibitor 
of senescence and p14-ARF, an inhibitor of p53 activation.49, 56  This deletion has a negative 
impact on prognosis. 57 
While in GCB type diffuse large B-cell lymphoma, BCL-2 is commonly deregulated by 
translocations, alternative mechanisms of BCL-2 up-regulation, such as gain or amplification 
of 18q21, are more frequently seen in the ABC subgroup. BCL-2 is a target gene for nuclear 
factor (NF)-κB, and in ABC type diffuse large cell B cell lymphoma, BCL-2 up-regulation may 
be mediated through the NF-κB pathway. In the ABC subgroup, bcl-2 expression is associated 
with poor survival.58 BCL-2 may act as an anti-apoptotic factor in this subgroup, but it may 
also serve as a marker for events that are responsible for poor prognosis, such as NF-κB 
activation.59, 60 
The NF-κB comprises a family of transcription factors that control genes implicated in B-cell 
activation, proliferation and resistance to apoptosis. The NF-κB family has five members: p65 
(RelA), p50 (NF-κB1), p52 (NF-κB2), RelB and REL. Two signaling pathways account for the 
activation of NF-κB. The classical pathway activation is normally triggered in response to 
inflammatory stimuli. Signal transduction events lead to activation of the IκB kinase (IKK) 
complex resulting in phosphorylation and proteasomal degradation of IκB. Heterodimers 
and homodimers of p50 and p65 can then be translocated to the nucleus to regulate gene 
transcription. The alternative pathway is triggered, amongst others, by certain members of the 
tumor-necrosis factor (TNF) cytokine family, eventually leading to processing of the p52 precursor 
subunit into active p52 translocating to the nucleus and forming a heterodimeric complex with 
RelB.61 Constitutive activation of NF-κB has been implicated to play a role in the pathogenesis of 
different types of haematological malignancies.62, 63 It seems generally involved in ABC type diffuse 
large B cell lymphoma and is required for survival of ABC type diffuse large B cell lymphoma 
cells in vitro.64 The role of constitutive NF-κB pathway activation in lymphomagenesis has raised 
interest in its potential as a target for therapeutic interventions, 65 66 61 specifically in ABC-type 
diffuse large B-cell lymphoma, as inhibition of the NF-κB pathway in vitro was shown to be 
selectively toxic to ABC type diffuse large B cell lymphoma cell lines and not to GCB type cell 
lines.64 
Recent studies, including ours, have focused on the use of immunohistochemistry to identify 
risk groups. In 2004 Hans et al. developed an algorithm applying immunohistochemical 
parameters, the expression of CD10, BCL-6 and MUM1/IRF4, to define the two prognostic 
groups of germinal center B cell phenotype and activated B-cell phenotype of nodal diffuse 
large B-cell lymphoma, thus avoiding the limitations of fresh tissue and costly technology 
of gene expression profiling.67 BCL-6 and CD10 proteins are considered germinal center 
(GC) markers, and MUM1/IRF4 denotes the final step of intra-GC B-cell differentiation and 
activation. More recently, a consortium of hematopathologists improved on the Hans method 
by employing a different combination of immunostains, i.e. GCET1, CD10, BCL-6, MUM1/





It is clear that diffuse large B cell lymphoma is a heterogeneous disease group. Even within the 
group of extranodal diffuse large B cell lymphoma, clinical outcome between the specific sites is 
quite variable. The scientific development in diffuse large B cell lymphoma research during the 
course of our project illustrates the ongoing evolution in risk stratification for lymphomas. The 
prognostic impact of grouping activated B cell type versus germinal center B-cell type diffuse 
large B-cell lymphoma has been described extensively in literature now, with usually a poorer 
prognosis for the ABC subtype. However, clinical evidence in the form of a large, prospective 
trial is still lacking. The knowledge on the role of BCL-2 up-regulation and its influence on 
prognosis depending on the lymphoma phenotype is increasing. Constitutive NF-κB pathway 
activation plays a major role in lymphomagenesis, but the exact mechanisms are still poorly 
understood.  Moreover, many of the techniques necessary for subtyping diffuse large B cell 
lymphoma according to the various risk stratification models, such as cDNA microarray and 
array-comparative genomic hybridization (array-CGH), are not available in routine patient care 
yet. It is also still unclear whether pathogenetic models discovered in nodal diffuse large B-cell 
lymphoma are applicable to the different extranodal lymphoma subtypes, such as primary 
diffuse large B cell lymphoma of bone. The expanding knowledge on lymphoma-associated 
biologic processes can help identify targets for the development of new therapeutic agents. At 
this moment, however, the novel treatment regimes are still experimental. The progress in risk 
stratification has not yet changed the standard R-CHOP treatment regimen for the individual 
patient. 
With this thesis, we hope to define the entity of primary diffuse large B cell lymphoma of bone 
more clearly by increasing the understanding of this very specific and rare subtype of diffuse 
large B cell lymphoma. Ultimately, ongoing lymphoma research will provide insights that lead 
to an improved, tailored treatment regimen for all diffuse large B cell lymphoma patients.
Scope and outline of the thesis
This thesis focuses on the clinico-pathological aspects of primary diffuse large B cell lymphoma 
of bone, a rare subtype of extranodal diffuse large B cell lymphoma. Improved insight of the 
pathophysiology of this bone tumor can be employed to acquire a better understanding of 
the wide range of different diseases grouped together under the name of diffuse large B cell 
lymphoma. 
In chapter two, we investigated the clinical course of a large cohort of 60 primary diffuse 
large B cell lymphoma of bone patients, which we selected from the files of the Netherlands 
Committee on Bone Tumors. We completed follow-up data until time of death or date of 
last follow-up. At the time of our research, no uniform directives for classification, treatment 
and prognosis were available yet. The objective of the study was to document patient and 
tumor characteristics of this cohort, with emphasis on histological subtype, substantiated by 
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immunohistochemistry, and to define factors affecting prognosis, including the parameters of 
the IPI risk index. 
In chapter three, we studied the MRI characteristics of 29 primary diffuse large B cell 
lymphoma of bone patients. Literature on the presentation of MR imaging features of primary 
diffuse large B cell lymphoma of bone is relatively scarce and contradictory. There is an ongoing 
debate as to whether there is a uniform imaging pattern in primary lymphoma of bone. We 
aimed to assess the imaging characteristics of primary lymphoma of bone and to asses the 
rate of a non-aggressive MR imaging appearance, by evaluating various features known from 
literature, with emphasis on cortical bone manifestation and marrow and soft-tissue signal 
characteristics.
In chapter four, we studied multiple immunohistochemical markers and their possible 
prognostic influence in primary diffuse large B cell lymphoma of bone. Immunohistochemical 
studies on primary diffuse large B cell lymphoma of bone are rare, probably because of 
the limited availability of tissue specimens of this disorder and technological difficulties in 
handling osseous tumor material. In nodal diffuse large B-cell lymphoma, individual markers 
have been shown to have a prognostic influence on survival. We determined the prognostic 
significance of BCL-6, CD10, MUM1, BCL-2, p53, CD30 and CD44. With the help of these 
markers we investigated the possible germinal center derivation in primary diffuse large B cell 
lymphoma of bone. 
In chapter five, we described the first array-CGH study of primary diffuse large B cell lymphoma 
of bone. Recent studies report that this technique can be used to classify lymphomas into the 
clinically and biologically relevant phenotypes: GC-like and ABC/non-GC-like, and possibly 
this technique can reveal differences in oncogenic mechanisms. We investigated genomic 
alterations in 9 cases of primary diffuse large B cell lymphoma of bone using this technique 
and analysed the results in the context of data available from literature on studies of other 
distinct subtypes of extranodal diffuse large B cell lymphoma such as skin, central nervous 
system and testis. 
In chapter six, we described the first study on the nuclear factor (NF)-κB signaling pathway in 
primary diffuse large B cell lymphoma of bone. The NF-κB comprises a family of transcription 
factors that control genes implicated in B-cell activation and proliferation. Constitutive 
activation of this pathway can contribute to tumorigenesis and chemotherapy resistance and 
is shown to be involved in tumor cell survival in several types of lymphomas, including nodal 
diffuse large B cell lymphoma. Two major pathways account for the activation of NF-κB, 
the classical pathway and the alternative pathway. We investigated both pathways of NF-κB 
activation by immunohistochemistry and evaluated its clinical parameters in a large cohort of 
50 primary diffuse large B cell lymphoma of bone patients.
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Primary non-Hodgkin’s lymphoma of 
bone: a clinicopathological investigation 
of 60 cases 
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A retrospective analysis of patients presenting with primary lymphoma of bone (PLB) was 
performed to determine clinical factors affecting prognosis in relation to histological subtype 
and treatment outcome. Data from 106 patients, presenting witha PLB between 1943 and 
1996, were retrieved from the files of the Netherlands Committee on Bone Tumours and 
Leiden University Medical Centre. The lymphomas were reclassified according to the REAL 
and updated Kiel classification. The clinical presentation, survival and prognostic factors were 
investigated. Sixty patients had sufficient clinical information and adequate follow-up to be 
included in the study. All 33 PLB that could be immunophenotyped were of B cell origin. 
According to the REAL classification, most PLB were large (B) cell lymphomas (92%) and 
according to the Kiel classification 45% of the tumours were centroblastic multilobated. PLB 
presented most often in the long bones (48%), with Ann Arbor stage I (46%), II (16%), IV 
(16%) and unknown (20%). Stage IV disease was exclusively caused by the presence of multiple 
bone lesions. Notwithstanding the heterogeneous treatment, the 5 year overall survival was 
61%; 46% of patients were progression free at 5 years. Patients at presentation older than 60 
had a worse overall survival (76% vs 37%, P = 0.0002) and a worse progression free period 
(58% vs 28%, P = 0.0073). Patients with the immunoblastic subtype had a worse survival than 
the centroblastic mono/polymorphic subtype or the centroblastic multilobated subtype (P = 
0.015). Primary lymphoma of bone represents an uncommon bone tumour with a relatively 
homogeneous morphology and clinical behaviour. Compared to other aggressive lymphomas, 
PLB have a favourable prognosis.
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Introduction 
Primary lymphoma of bone (PLB) is a rare disease, first described by Oberling in 1928.1 It was 
not until 1939 that Parker and Jackson2 described 17 cases of ‘primary reticulum cell sarcoma 
of bone’ and established PLB as a distinct clinical entity. Even today the diagnosis of PLB 
can be difficult due to the relatively non-specific radiographic appearance and the sometimes 
profound proliferation of reactive fibroblasts at the histological level.3 Thus, PLB can be 
erroneously interpreted as a primary skeletal tumour of non-lymphoid origin such as Ewing’s 
sarcoma or malignant fibrous histiocytoma. 
Most studies on PLB published so far describe small groups of patients. In many studies stage 
IV tumours were excluded and patients were only treated with radiotherapy.4–11 Uniform 
directives for classification, treatment and prognosis are still lacking. We describe a relatively 
large group of 60 patients with clinico-radiologically and histologically documented PLB, 
collected from the files of the Netherlands Committee on Bone Tumours and the Leiden 
University Medical Centre. Our objective was to document patient and tumour characteristics 
of this cohort with emphasis on histological subtype, substantiated by immunohistochemistry 
and to define factors affecting prognosis for PLB. 
Materials and methods 
Patients 
The files from the registry of the Netherlands Committee on Bone Tumours with diagnosis 
codes ‘malignant lymphoma’, ‘reticulum cell sarcoma’ or ‘lymphosarcoma’ involving bone 
were reviewed. This registry contains more than 11000 cases, collected between 1943 and 
1996 and includes clinical data at presentation, histological slides of the tumour and complete 
radiographic documentation. In addition to these cases, patients registered at the Leiden 
University Medical Centre with a diagnosis of primary non-Hodgkin’s lymphoma of bone 
were selected. A total number of 106 patients were identified. Of this group 30 patients were 
excluded because of a different diagnosis after review of the histological slides, combined with 
new immunohistochemical data or clinical data obtained at follow-up. These cases included 
Ewing’s sarcoma (n = 8), acute lymphoblastic leukaemia/lymphoma (n = 5) or Burkitt’s 
lymphoma/leukaemia (n = 3), acute myeloid -leukaemia (n = 3), multiple myeloma (n = 3), 
secondary bone involvement of NHL (n = 3), Hodgkin’s lymphoma (n = 2) or inappropriate 
histological material for review (n = 3). For a diagnosis of PLB, patients had to present with a 
histologically proven lymphoma arising within the medullary cavity of a bone, with or without 
regional lymph node involvement. Multiple bone lesions were acceptable as long as there was 
no evidence of earlier lymphomatous involvement elsewhere. 
A questionnaire was sent to the collaborating hospitals to obtain follow-up data for the 76 
selected patients. Follow-up data were successfully collected for 60 patients, whereas 16 
patients were lost to follow-up. The last date of follow-up was December 1996. From these 
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60 cases, 54 were retrieved from the Netherlands Committee on Bone Tumours and six from 
the Leiden University Medical Centre. The patient records were reviewed for the following 
parameters: sex, tumour localisation, tumour diameter (5 cm, 5 cm as measured on the 
radiographs), treatment, response to treatment, date and site of relapse or progression if 
applicable, date of last follow-up or date of death and cause of death. The clinical parameters 
age, stage, serum LDH level, number of extranodal sites and performance status according 
to the Eastern Cooperative Oncology Group scale of the International Prognostic Index (IPI) 
for aggressive non-Hodgkin’s lymphoma12 were used. Stage was defined according to the Ann 
Arbor staging classification. Serum LDH level was recorded as 1.5× normal or 1.5 × normal. 
The number of extranodal sites was defined as the number of all extranodal sites including 
the bone localisations. According to the IPI12 performance status was grouped as 0 or 1 (the 
patient was ambulatory) or 2, 3 or 4 (the patient was not ambulatory). 
Histological classification and immunohistochemistry 
The pathological diagnosis was established according to the REAL classification13 and updated 
Kiel classification14 using standard histological criteria and, if possible, immunohisto-
chemistry. Immunohistochemical studies were performed on paraffin-embedded material, 
and could be interpreted in 33 of 60 cases. In the remaining 27 cases the material was not 
available or inappropriate due to decalcification artefacts. The antibodies used in this study 
included leukocyte common antigen (CD45) (Dakopatts, Copenhagen, Denmark), L26 as a B 
cell marker (CD20) (Dakopatts), and a T cell marker (CD3) (Dakopatts). In some cases BerH2 
(CD30) (Dakopatts) was also used. Immunohistochemical procedures were performed as 
detailed previously.15 
Staging 
Staging investigations performed varied over time and patients were staged retrospectively 
according to the Ann Arbor staging classification. For the purpose of this study, staging 
was defined as complete if it included: (1) a chest X-ray or a CT scan of the chest; (2) 
lymph-angiography or CT-scan or echography of the abdomen and pelvis; (3) bone marrow 
biopsy; and (4) total body bone scintigraphy or MRI. Defined as such 20 patients were completely 
staged and 40 were not. The investigation most frequently missing in the incompletely staged 
patients was a bone marrow biopsy. 
Treatment 
Since 1943 a wide variety of therapies has been used, including radiotherapy, chemotherapy 
and surgery in various combinations. The patients receiving chemotherapy were subdivided 
into a group treated with CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) 
or CHOP-like therapy and a remaining group with mostly non-adriamycin containing single 
agent therapy. Surgery consisted of either resection or amputation. As patient numbers were 
too small to perform statistical analysis on all the different treatment combinations, we selected 
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the following groups (Table 1): group 1 (n = 5) was treated with radiotherapy alone (c−r+s−), 
group II (n = 24) was treated with radiotherapy and chemotherapy (c+r+s−), and group III (n 
= 11) was treated with radiotherapy, chemotherapy and surgery (c+r+s+). The remaining 20 
patients received either other combinations of therapy or inadequate therapy (for example 
radiotherapy <30 Gy). In group II, 15 of 24 patients and in group III, six of 11 patients received 
adriamycin containing (CHOP or CHOP-like) chemotherapy. 
Response to treatment was recorded as complete remission, partial remission (>50% reduction 
of tumour), no change or progressive disease. 
Survival analysis 
For the whole cohort (n = 60) the overall survival time was calculated from time of diagnosis 
until time of death or until date of last follow-up (December 1996). The progression-free 
period was calculated from the date of diagnosis to the date of progression or relapse or to 
last contact in case the patient was progression free. Patients who had progressive disease in 
response to treatment were considered to have a progression free period of 0 months. The 
five patients of whom the response to treatment could not be determined were excluded from 
the progression-free period analysis. Survival curves were calculated according to the Kaplan 
and Meier method; survival analysis was performed using the log-rank test. We performed 
univariate analysis on the following factors: sex, tumour localisation, tumour diameter, 
histological subtype, treatment, age, stage, and the level of serum LDH. 
Results 
Patient characteristics 
Patient characteristics are summarised in Table 1. The group consisted of 39 males and 
21 females, a ratio of 1.8 consistent with other studies.8 The age of the patients varied 
from 13 to 86 years (median 48). The PLB most often presented in the long bones (29 
localisations, 48%), of which seven localisations (12%) presented in the upper limb and 22 
localisations (36%) in the lower limb (Figure 1). In 10 patients (16%) more than one bone 
localisation was found. The symptoms at presentation were local pain and/or a palpable mass. 
Three patients presented with a pathologic fracture. No B symptoms were reported in this 
cohort. 
Clinical staging 
In 48 patients the stage could be assigned. Twenty-eight patients presented with stage I disease, 
10 with stage II, and 10 with stage IV (Table 1). Twenty-eight out of all 48 patients and 21 out 
of 38 patients with stage I or II disease had undergone an incomplete staging procedure. All 
stage II tumours had lymph node involvement near the site of the bone localisation. All stage 
IV tumours had more than one bone localisation and none had bone marrow or other distant 
organ involvement. Three of the 20 completely staged and seven of the 28 incompletely staged 
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Table 1. Summary of clinical, histological and therapeutical para¬meters 
Parameter No. of Percentage
 patients ()a 
Sex
 Male 39 65
 Female 21 35 
Stage
 I 28 46
 II 10 16
 III 0 0
 IV 10 16
 Unknown 12 20 
 Completely staged 20 33
 Incompletely staged and unknown 40 67
Histology
 Follicle center cell, diffuse 2 (1) 3
 Large B cell 55 (32) 92 
  Centroblastic mono/polymorphicb 18 (12) 30
  Centroblastic multilobatedb 27 (15) 45
  Immunoblasticb 10 (5) 16 
 Anaplastic large cell 2 (0) 3
 Immunocytoma 1 (0) 2 
Therapy
 Radiotherapy only 5 8
 Radiotherapy and chemotherapy 24 40
 Radiotherapy, chemotherapy and surgery 11 18
 Other combinations 20 33 
Chemotherapy
 CHOP or CHOP-like 23 38
 Other chemotherapy 15 25 
Response to therapy
 Complete remission 29 48
 Partial remission 5 8
 No change 1 2
 Progressive disease 20 33
 Unknown 5 8 
aImmunohistochemistry performed.
bUpdated Kiel classification.14 
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patients had stage IV disease. This makes understaging in the latter group somewhat unlikely. 
In the remaining 12 patients the stage could not be determined. 
Histological classification and immunohisto-chemistry 
The results of the histological analysis and immunohistochemistry are given in Table 1. All 33 
out of 60 lymphomas that could be immunophenotyped were of B cell origin. Based on the 
routine histological slides and limited immunophenotypic data available, almost all lymphomas 
(92%) were large (B) cell lymphomas according to the REAL classification.13 According to the 
updated Kiel classification14 45% of the PLB were of the centroblastic multilobated subtype. 
The two anaplastic large cell lymphomas could not be immunophenotyped, and therefore, it 
cannot be excluded that they belonged to a subset of large B cell lymphomas with anaplastic 
morphology.14 
Response to treatment, survival and prognostic factors 
Forty-eight percent (n = 29) of 60 patients achieved complete remission, 8% partial remission, 
2% showed no change, 33% had progressive disease and in 8% of the patients response to 
therapy could not be determined (Table 1). 
Figure 1. Tumor localisation. PLB most often presen-
ted in the long bones (50%): in the upper limb (12%) 
and in the lower limb (38%). Ten patients presented 
with more than one bone localisation. The site of the-
se multiple localisations are included in the figure (70 
localisations in total). 
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The mean follow-up for the whole cohort was 174 months, ranging from 1 to 296 months. At 
5 years after diagnosis 46% of the patients were free of progression. The 5-year overall survival 
was 61% for all patients, 66% for patients with stage I and II and 50% for patients with stage IV 
(Figure 2). Nine out of 29 patients relapsed. The localisation of the relapses were bone (n = 3), 
lymph nodes (n = 3), liver (n = 1), lungs (n = 1) and breast (n = 1). Twenty-three patients died 
during follow-up. The cause of death was primary refractory disease in 18 patients, relapse in 
four patients and unrelated to NHL in one patient. 
For statistical purposes we only included the three largest histological groups (centroblastic 
mono/polymorphic, centroblastic multilobated and immunoblastic) in the survival and 
Figure 2. Survival in prima-
ry NHL ofbone. The 5 year 
overall survival was 61% for 
all patients (n = 60; upper-
panel). At 5 years after diag-
nosis 46% of patients were 
free of progression (n = 60 
patients, lower panel).
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progression-free survival analysis. The immunoblastic subtype (as defined by the Kiel 
classification14 containing 90% or more immunoblasts) had a statistically significantly shorter 
overall survival and progression-free period than the other subtypes (P = 0.015 and P = 0.05, 
respectively; Figure 3). 
As a consequence of often incomplete clinical data the risk groups defined in the International 
Prognostic Index could not be determined. We analysed the influence of the individual factors 
age, sex, primary localisation, tumour size, stage and serum LDH on survival. To prevent bias, 
only the cases with sufficient data for all six parameters were included in the univariate analysis. 
Age was a significant prognosticator, with a 5 year overall survival of 76% for patients younger 
than 60 years and 37% for patients of 60 years and older (P = 0.0002; Figure 4) and a 5-year 
progression-free period of 58% vs 28% (P = 0.0073). As there was no difference in survival 
between stage I and stage II patients, we analysed stage I and II against stage IV. Although there 
was a trend towards worse survival for stage IV, it was not statistically significant (P = 0.56). An 
elevated serum LDH was associated with decreased overall survival (P = 0.25) but this did not 
reach statistical significance, probably because of the relatively small numbers of patients who 
could be analysed (n = 38). No statistically significant effect on survival was found after univariate 
analysis of the other prognostic factors such as sex, tumour localisation, and tumour size. 
Survival was not statistically different for the three selected treatment combinations. 
The overall survival of patients treated with CHOP or CHOP-like chemotherapy was not 
significantly better than the survival of patients treated with other types of chemotherapy (P = 
0.17). The progression-free period, however, was significantly longer for patients treated with 
CHOP or CHOP-like therapy, with a 5 year progression-free period of 58% vs 27% (data not 
shown). A confounding factor is that adequate staging and treatment are related: after 1975 
both staging procedures (introduction of CT scan) and treatment modalities (introduction of 
CHOP or CHOP-like chemotherapy) improved. To investigate the possible impact of accuracy 
Figure 3. Comparison of tu-
mor subtype related to over-
all survival. Patients with the 
immunoblastic subtype had 
a worse overall survival than 
the centroblastic multiloba-





of diagnostic procedures on survival we analysed the role of complete staging: patients with 
complete staging had a slightly better prognosis with respect to overall survival, but it did not 
prove statistically significant in univariate analysis (P = 0.48). 
Discussion 
The presentation of NHL as a localised bone tumour is relatively uncommon. Any study of the 
pathophysiology of PLB and on prognostic factors is complicated by the small patient numbers 
and by the fact that the results of earlier studies are often not comparable to each other.4-6 
We studied a relatively large and representative group of patients, diagnosed and treated 
between 1943 and 1996. Patients were selected by reviewing all cases previously diagnosed as 
malignant lymphoma, lymphosarcoma or reticulum cell sarcoma. Since we did not review all 
primary bone tumours, we cannot exclude that especially in the early years of the registry, a 
few tumours were misdiagnosed as Ewing’s sarcoma or, in case of excessive fibrosis, as sarcoma 
not otherwise specified, and thus were not included here. 
We show that the patients display a homogeneous pathological and clinical presentation as 
well as clinical behaviour. Histologically, almost all PLBs were of the large B cell type, and half 
of these tumours were of the multilobated centroblastic subtype. The very high frequency of 
this latter subtype had been reported previously.16 The majority of patients presented with 
pain and/or a palpable mass, most often at a single localisation in one of the long bones. 
Approximately one quarter of the patients presented with multiple bone lesions, which is in 
accordance with other studies.9 Of note, these patients made up the entire group of stage IV 
patients. In line with a specific pattern of dissemination and homing of tumour cells in PLB, 
three of nine patients had bone localisations upon relapse. 
Figure 4. Comparison of 
age groups under and over 
60 years related to overall 
survival. The 5-year overall 
survival was 76% for the pa-
tients younger than 60 years 
(n = 37) and 37% for the pa-
tients of 60 years and older 
(n = 23).
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The initial treatment for these tumours, before chemotherapy became available, was 
radiotherapy or surgery. Several studies suggest that the combination of chemotherapy and 
radiotherapy is the best treatment, as a consequence of which resection or amputation can 
be prevented.4,17,18 In this cohort the overall 5 year survival was 61%. This is surprisingly high 
when the heterogeneous treatment schedules over the years of the study and the inclusion of 
stage IV patients are taken into account. Although survival was not statistically different for 
the three selected treatment combinations, patients treated with CHOP or CHOP-like therapy 
had a longer progressionfree period than patients treated with other types of chemotherapy. 
Although our data are derived from a retrospective analysis of a very heterogeneous study 
group, some conclusions may be drawn with respect to prognostic factors. Consistent with 
previous reports,10,11 immunoblastic lymphoma as defined by the updated Kiel classification,14 
had a worse prognosis than other large B cell lymphoma subtypes. In the past, the clinical 
parameters used to predict prognosis in PLB, were tumour stage and localisation.7,8,10,11 
We found these prognostic factors not easily applicable to PLB. Furthermore, as in other 
extra-nodal lymphomas, in PLB prognosis is not strongly affected by regional lymph node 
involvement: there was no difference in survival between stage I and stage II tumours and 
just a trend towards worse prognosis in stage IV tumours. This underlines that the Ann Arbor 
classification is not suitable for staging and predicting prognosis in PLB. Of note, many studies 
on PLB excluded patients with stage IV disease, partly in an effort to eliminate malignancies 
in which bone involvement is secondary.4–6,19 This exclusion is not supported by our data that 
stage IV disease is mostly determined by multiple, osseous localisations. 
Tumour localisation was no significant prognostic factor, neither could we confirm the 
suggestion that tumour localisation within the pelvis, ribs or vertebra is associated with a 
worse prognosis.8 It is interesting that more than 50% of the stage IV tumours had at least one 
localisation in the pelvis, the vertebra or the ribs. 
In conclusion, we propose that primary non-Hodgkin’s lymphoma of bone be acknowledged 
as a specific clinicopathologic entity. Morphologically, PLB forms a homogeneous group and 
dissemination is often restricted. Furthermore, PLB patients seem to have a better survival than 
other NHL patients, even with therapy that is considered inadequate nowadays. Finally, this 
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Purpose. To assess the heterogeneity of magnetic resonance (MR) imaging characteristics in 
primary lymphoma of bone (PLB), in particular the non-aggressive appearance. 
Subjects and methods. In a retrospective study, MR imaging features were analyzed in 29 
patients with histologically proven PLB. The following parameters were evaluated: tumor 
size, bone marrow and extension into soft tissues, signal characteristics of bone marrow and 
soft-tissue com ponents, including enhancement, and involvement of cortical bone (complete 
disruption, focal destruction, permeative destruction and cortical thickening). 
Results. PLB presented with extension into the soft tissue in 22 (76%) of 29 patients, was only 
subtle in three of these 22 patients, and was absent in seven patients. Signal intensity (SI) of the 
soft-tissue part was most frequently homogeneously isointense with muscle on T1-weighted 
images (90%) and high on T2-weighted images (91%). Enhance ment was predominantly 
homogeneous and diffuse (82%). In 93% of patients cortical bone appeared abnormal: among 
those patients complete cortical disruption was seen in 28%, with extension into soft tissues 
in all but one patient; a permeative pattern of destruction was present in 52% of patients, 66% 
of these had an associated soft-tissue mass. Two patients with normal-appearing cortical bone 
had no extension into soft tissues. In two patients focal cortical destruction was noticed; in one 
patient cortical bone was homogeneously thickened, and in one patient PLB was selectively 
localized within the cortical bone. SI of the bone marrow tumor component was more 
frequently heteroge neous (in 54%), compared with the soft-tissue component, being high on 
T2-weighted images in 89%, intermediate in 7% and low in 4%. Similarly, enhancement was 
heteroge neous in 59%. 
Conclusion. The MR imaging appearance of PLB is variable. In 31% of PLB patients, the tumor 
was intra osseous, with linear cortical signal abnormalities or even normal-appearing or 
thickened cortical bone without soft -tissue mass, and, as such, PLB may not infrequently look 
non-aggressive on MR imaging. 
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Introduction 
Primary lymphoma of bone (PLB) is a rare disease, accounting for less than 1% of all non-
Hodgkin’s lymphoma (NHL) cases and 3–5% of all extra-nodal lymphoma cases [1-3]. According 
to the World Health Organization (WHO) classification of hematological malignancies, it is a 
distinct cinico-pathological subtype of extra-nodal, diffuse, large B-cell lymphoma (DLBCL) 
with a relatively homogeneous pathological and clinical presentation [4, 5]. Almost all tumors 
are of the large B-cell type, morphologically com posed of large centroblastic cells, frequently 
with multi lobated nuclei [5-8]. The prognosis of PLB, depending on staging and histologic 
classification, is favorable following combined modality (chemo-and radiation) therapy, with a 
5-year overall survival rate that extends to 88% [7, 9–12]. 
Debates are ongoing as to whether there is a uniform imaging pattern in PLB, in particular on 
the magnetic resonance (MR) imaging characteristics of PLB. Some authors have stated that 
a tumor with normal-appearing cortical bone and a substantial soft-tissue mass is likely to be 
a non-Hodgkin’s lymphoma [13, 14]. One study focused on the hypointense signal intensities 
on T2-weighted images as a feature that may be characteristic of PLB as opposed to other 
malignant tumors [15]. In other studies MR findings were found to be non-specific and not 
useful for differentiating PLB from other small, blue, round cell tumors, including Ewing’s 
sarcoma and small cell osteosar coma and (in older age groups) tumors such as metastases 
of carcinoma and plasmacytoma [16]. In addition, the plain radiographic appearance of PLB 
differs from virtually normal to a severely permeative pattern of bone destruction with a 
blastic, lytic or mixed appearance, and, as such, is also non-specific [17–19]. 
The order of differential diagnosis is, therefore, mainly based on the patient’s age, race and 
clinical features. 
To assess the homogeneity or heterogeneity of MR imaging characteristics in PLB, and to 
assess the rate of a non-aggressive MR imaging appearance, we evaluated various features 
known from the literature, with emphasis on cortical bone manifestation and marrow and 
soft-tissue signal characteristics, in 29 patients in the present retro spective imaging study. 
Subjects and methods 
The files of 29 patients with a histologically proven diagnosis of PLB, and MR imaging 
studies available at the time of diagnosis, were retrieved from the archive of the Netherlands 
Committee on Bone Tumors, representing the period between 1989 and 2004. All histological 
diagnosis were re-assured for this study. 
Patients’ characteristics
The study group consisted of 29 patients, 14 female and 15 male. In the majority of the patients 
the tumors were located in the femur (n=13) or humerus (n=6). 
Other tumor sites included the ilium (n=4), scapula (n=2), tibia, acetabulum, lumbar vertebra and 




Since the Netherlands Committee on Bone Tumors serves as a consulting medium for the 
entire country, MRI studies were performed on different imagers with field strengths between 
0.5 T and 1.5 T. T1-weighted spin echo (SE) sequences were available for 28 patients; TRs 
varied from 400–800 ms, with TEs from 12–25 ms. T2-weighted (fast) SE sequences were 
available for 29 patients, with fat selective pre-saturation sequences for 14 patients. TRs varied 
from 2,000–7,000 ms, with TEs from 70–130 ms. Contrast-enhanced, T1-weighted, SE series 
after intra venous injection of 0.2 mmol gadopentetate dimeglumine (Gd-DTPA) were available 
for 25 of 29 patients, with fat selective pre-saturation sequences for ten patients. A dynamic 
contrast-enhanced sequence was used for only three patients. For all patients a combination of 
axial and longitudinal (either coronal or sagittal) images was avail able for evaluation. 
Imaging evaluation 
The following parameters were evaluated in consensus by two experienced musculoskeletal 
radiologists: 
Tumor size Tumor dimensions were established by mea suring length, width and depth, assessed 
from the combi nation of axial and longitudinal images. 
Extension into the soft tissues Presence or absence of a soft tissue component, defined as a mass 
beyond the margins of cortical bone and periosteum, was determined. 
Soft-tissue edema Soft-tissue edema was considered to be present when areas of peri-lesional 
high signal intensity (SI) were noticed on T2-weighted sequences and/or contrast enhanced T1-
weighted sequences in an ill-defined feathery pattern, without disruption of the fascial plane
Signal intensities of soft-tissue part SIs were defined as predominantly high, intermediate, low 
or mixed, relative to muscle SI, assessed on both T1-and T2-weighted sequences. Furthermore, 
homogeneity or heterogeneity of the SI on T2-weighted images was assessed. 
Enhancement of soft-tissue part The pattern of tumoral enhancement on T1-weighted Gd-
DTPA-enhanced sequences (absent, peripheral or diffuse) was recorded, as well as the 
homogeneity or heterogeneity.
Cortical bone destruction Appearance of the cortical bone was determined as normal or 
abnormal on both T1-and T2 weighted images. Abnormal cortical bone appearance was 
subdivided into complete cortical destruction (normal low SI, completely replaced by high 
signal intensity of tumor), focal destruction (normal low signal intensity, partially replaced 
by high SI of tumor with focal disturbance of cortical integrity), permeative destruction (fine 
linear pattern of intracortical high SI, without disturbance of cortical integrity) or cortical 
thickening (thickening of cortical bone, without signal abnormalities).
Bone marrow involvement SIs of the bone marrow com ponent and homogeneity were assessed 
on T1-and T2 weighted sequences, compared with muscle SI (higher, equal/intermediate, lower, 
mixed) and opposed to the high SI of normal bone marrow. Tumor margins were defined as 
sharp or unsharp. 
Enhancement of bone marrow component The presence or absence of intra-osseous tumoral 
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enhancement and the pattern (homogeneous, heterogeneous, focal, diffuse) of enhancement 
on static T1-weighted Gd-DTPA-enhanced sequences were determined. 
Histological classification and immunohistochemistry The pathology diagnosis was established 
according to the World Health Organization classification on biopsy material, using standard 
histological criteria and immunohistochemistry using antibodies directed against vimentin, 
CD45, CD3, CD20, CD79a, and CD99. Immunohistochemical staining was performed on 4 
μm sections of formalin-fixed, paraffin-embedded tissues, using standard procedures. In this 
study, all tumors were of the large B-cell type.
Results 
Tumor size The mean maximum tumor diameter was 11 cm (range 3–18 cm). 
Extension into the soft tissues Tumor extension into the soft tissues was apparent in 22 of the 29 
patients (Fig. 1) (76%), in three of these patients this was very discrete (Fig. 2). In the remaining 
seven patients (24%), the tumor was entirely confined to the intramedullary and/or cortical 
compartment (Fig. 3). 
Soft-tissue edema Peri-lesional soft-tissue edema was en countered in approximately half of the 
patients (15 out of 29, 52%), whereas, in the other 14 patients, it was absent. 
Figure 1. An 80-year-old male patient with primary non Hodgkin’s lymphoma of the proximal hu-
merus. Axial T1 weighted turbo-spin echo (TSE) (TR/TE 575/15 ms) images be fore (a) and after (b) 
Gd-DTPA administration, the latter se quence with fat-selective pre saturation. Intra-osseous tumor 
with circumferential substantial extension into the soft tissue. There is partly complete cortical dis-
ruption of cortical bone and otherwise permeative destruc tion shown as a fine linear pattern of ab-
normal increased cortical SI (a), even more con spicuous on contrast-enhanced images (b, arrow) 
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Figure 2. A 32-year-old female patient with primary non-Hodgkin’s lymphoma of the distal femur 
diaphysis. Axial T2-weighted fat-suppressed turbo-spin echo (TSE) (TR/TE 3799/80 ms) image 
(a) and axial T1-weighted contrast-enhanced fat-suppressed TSE (TR/TE 500/15 ms) image (b). 
Hetero geneous high SI (a) of intra osseous component and limited circumferential soft-tissue cuff. 
Heterogeneous enhancement. Permeated cortical bone with linear intracortical, increased SI, par-
ticularly seen on Gd-enhanced images (b, arrow)
Figure 3. A 26-year-old female patient with primary non Hodgkin’s lymphoma of the distal 
femur. Sagittal (a) and axial (b) T1-weighted contrast-enhanced fat suppressed turbo-spin echo 
(TSE) (TR/TE 600/20 ms) images. There is inhomoge neous enhancement of the intra osseous 
tumor, with normal appearing cortical bone and, besides enhancing periosteum, no associated 
soft tissue mass 
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Signal intensities of soft-tissue part Appearance on T1 weighted sequences could be assessed 
for 21 patients bearing tumors with extension into the soft-tissues: in 19 (90%) of these 21 
patients the SI was intermediate and equal to that of muscle. In two patients the SI was higher 
than for muscle. In 22 patients the SI on T2-weighted sequences could be assessed, being high 
(higher than that of muscle, lower than that of fat) in 20 patients (91%). This high signal was 
predominantly homogeneous in 18 of those 20 patients and heterogeneous in the other four. 
Figure 4. A 58-year-old 
male patient with primary 
non-Hodgkin’s lymphoma 
of the distal humerus. Axial 
T1 turbo-spin echo (TSE) 
(TR/TE 504/13 ms) (a) and 
T2-weighted TSE (5,927/80 
ms) image with fat-selective 
pre-saturation (b). Primary 
intra-osseous tumor with 
circumferential soft-tissue 
mass, homogeneously iso-
intense on T1 and high on 
T2-weighted sequences. 
Normal cortical thickness 
with discrete signal abnor-
malities on T1 (a, arrow), 
more conspicuous on T2-
weighted sequences (b) 
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Enhancement of soft-tissue part Enhancement of the soft tissue component of the tumor 
could be determined in 17 patients; for the other 12 patients contrast-enhanced studies were 
not available. Enhancement of the soft-tissue part occurred in all evaluable patients, being 
predominantly homogeneous and diffuse in 14 (82%) patients and heterogeneous in the other 
three patients (Fig. 1). 
Cortical bone destruction For two of the 29 patients the entire cortical bone was scored 
as normal. In those two patients there was also no extension into soft-tissue (Fig. 3). In 27 
patients (93%) the cortical bone was abnormal. A permeative cortical destruction pattern 
was noticed for a small majority of patients (15 of 29, 52%). In ten of these 15 patients, an 
associated soft-tissue mass was apparent (Fig. 4); however, in two patients, this was absent. In 
the remaining three patients only limited extra-cortical abnor malities were present (Fig. 2). 
Complete cortical disruption was found in eight patients (Fig. 1) (28%). All but one of these 
eight patients had significant extension into the soft tissue. Focal destruction was seen in two 
patients, and homogeneous cortical thickening in one patient. Moreover, selective intracortical 
tumor localization was encountered in one other patient. 
Bone marrow involvement Signal intensity of the intra osseous tumor component on T1-
weighted images could be assessed in 26 patients being predominantly intermediate (equal to 
muscle) in 25 patients (Figs. 1, 4) and predom inantly low (lower than muscle) in one patient. 
In three patients (12%) of the former group, a combination of intermediate and low signal 
intensity was found. Demarcation in the longitudinal extent was scored as sharp in 11 and 
shaded in nine patients. On T2-weighted images (available in 28 patients) the SI of the bone 
marrow compartment was high in 25 patients (89%), intermediate in two patients (7%) 
and low in one patient. The SI of the bone marrow tumor component was homogeneous in 13 
of 28 patients (46%), however, inhomogeneous in 15 patients (54%). (Figs. 2, 5). 
Enhancement of bone marrow component Enhancement of the bone marrow tumor component 
could be assessed in 23 patients. No enhancement was noticed in only one patient. The other 
22 patients showed enhancement, which was homogeneous in nine patients (41%), and 
heterogeneous in 13 patients (59%) (Figs. 2, 3, 5). 
Discussion 
Primary non-Hodgkin’s lymphoma of bone (PLB) is a rare entity among musculoskeletal tumors, 
and it is also un common among extra-nodal sites of NHL. The morphology of these lymphomas 
is identical to that of lymphomas at other sites, but the clinical course is often more protracted. 
Prognosis of PLB depends mainly on staging and on his tological classification, but, generally, 
the clinical outcome, after treatment with combined chemo-and radiation therapy, is favorable, 
with a 5-year overall survival rate rising to 88% [1–5, 9–11, 18, 20]. On the other hand, Lewis 
et al. reported a 5-year survival rate of 58% and no statistically significant difference between 
PLB and sys temic bone lymphoma [6]. With regard to histological subtype, tumor localization 
and clinical presentation, patients with PLB display homogeneous clinicopathologi cal features 
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[4, 5]. Almost all tumors are localized in long bones (particularly the femur, tibia, pelvis and 
humerus), and patients present with pain and/or a palpable mass. The literature describes 
a significant male preponderance, which is not confirmed in this present study. Although 
PLB presents in a wide age range of patients, evenly distributed among the second through 
eighth decades of life, in general, it is more frequently encountered in patients over 30 years 
of age, with a peak incidence in the fifth decade, in contrast to that of Ewing’s sarcoma and 
osteosarcoma [6, 8, 10, 11, 13, 14, 18]. In the latter patient group, a significant decrease in 
incidence is found beyond the third decade. In our study group of 29 patients a broad range of 
ages at presentation was also found (19–81 years); the median age was 40 years. 
Plain radiographs of PLB often show destructive bone lesions, generally with periosteal 
layering and cortical disruption. On the other hand, plain radiographs of PLB may appear 
virtually normal or non-specific and can be overlooked as being normal. As such, there is 
no specific conventional radiographic pattern, and the radiographic differential diagnosis of 
PLB includes a broad spectrum of both benign (including osteomyelitis) and malignant (such 
as osteosarcoma, Ewing’s sarcoma) lesions [8, 16-19]. These tumors and tumor-like lesions 
may demonstrate similar radiographic features but warrant different types of therapy. In this 
respect PLB is associated with a better prognostic outcome than that for other small round cell 
tumors. Literature on the presentation of MR imaging features of PLB is relatively scarce and 
contradictory. These studies, frequently with limited numbers of patients, mainly focused on 
the appearance of the cortical bone, relative to associated soft-tissue abnormalities, and on SI 
character istics [13-16, 18, 19, 21, 22]. Low SI on T2-weighted sequences has been mentioned 
as a feature of PLB, probably due to a high content of fibrous tissue [15]. We could not confirm 
Figure 5. A 29-year-old male patient with non-Hodgkin’s lymphoma of the proximal humerus. 
Axial T1-weighted contrast-enhanced (TR/TE 550/12 ms) (a) and T2-weighted (b) turbo-spin 
echo (TSE) (TR/TE 3,021/80 ms) images with fat-selective pre-saturation. Intra-osseous tumor 
localization with no extension into soft-tissue and heterogeneous high SI on both sequences.
38
CHAPTER 3
this feature to a great extent in our population. Low SI on T1-or T2-weighted sequences was 
present in only one patient each. Almost all tumors showed a non-specific combination of 
intermediate (equal to that of muscle) SI on T1-weighted sequences and high SI on T2 weighted 
sequences. 
Several studies on PLB and MR imaging focused on the pattern of cortical destruction in order 
to use it as a differentiating criterion. It was stated that a tumor with a normal (appearing) 
cortex and a substantial soft-tissue mass is likely to be lymphoma [13, 14]. MR imaging may 
show small linear foci of intermediate or high SI on T2-weighted sequences, penetrating the 
cortical bone. This MR pattern of permeative cortical destruction is, however, not specific 
to lymphoma. It can be seen in other small round cell tumors (in the younger age group) as 
well as in different metabolic and inflammatory processes, including hyper parathyroidism and 
osteomyelitis and, for instance, myeloma or metastatic carcinoma (in the older age group) [13, 
14]. In our study, cortical abnormalities were present in 93% of patients, and extension into 
the soft tissue was found in 76%, but various types of destruction and combinations with or 
without such extension were recognized (Table 1). A pattern of permeative cortical destruction 
with linear foci of abnormal SI was noticed in 15 of the 29 (52%) patients. Ten of these 15 
patients had a definite soft-tissue mass. In five patients, however, this was minimal or even 
absent. In 28% of our patient population complete cortical disruption could be appreciated; in 
all but one patient it was accompanied by a large soft-tissue mass. In another two patients, the 
cortical bone appeared to be completely normal, and in these patients there was no associated 
soft tissue mass. In one patient with histologically confirmed PLB the tumor was selectively 
located within the cortical bone, without further extension into the soft tissue and/or bone 
marrow involvement. In one patient the cortical bone was homogeneously thickened, a feature 
that can also be encountered in reactive processes (after trauma or infec tion). Peri-osteal or 
cortical lymphoma without medullary involvement is a very rare manifestation of NHL, but 
it has been previously described [23]. In this respect, it can be concluded that in patients with 
PLB the pattern of cortical destruction is heterogeneous and non-specific. 
MR imaging is the optimal modality to demonstrate the extent of bone marrow replacement 
by PLB, particularly using T1-weighted sequences [14, 24]. Multi-centric bone marrow disease 
is likely to be detected by longitudinal series with a large field of view. Signal intensities of the 
bone marrow component were non-specific in the present series, being intermediate on T1-
weighted sequences and high on T2-weighted sequences in almost all patients. In only three 
patients a combination of intermediate and low signal intensity was found. Demarcation in 
the longitudinal extent was scored as sharp in 11 and unsharp in nine patients. The SI of the 
bone marrow tumor component was homogeneous in 13 of 28 patients (46%); however, it 
was inhomogeneous in 15 patients (54%), which can be explained by the intermingling of 
normal bone marrow between areas of tumor. Contrast-enhanced images of the bone marrow 
showed a similar distribution; enhancement was diffuse and homogeneous in 41% and 
heterogeneous in 59% of the patients whose condition was eligible for evaluation. Opposed 
to the bone marrow component, the soft-tissue component, if present, was far more homoge-
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neous, both on T1-weighted contrast-enhanced images (82%) and as high SI on T2-weighted 
images (82%). 
The data obtained in this retrospective study demonstrate that, in contrast to the relatively 
homogeneous clinical and pathological presentation, the MR imaging features are not uniform 
in patients with PLB. Although the majority of our patients displayed a combination of definite 
cortical abnor malities (either permeative destruction or complete disrup tion) and extension 
into soft-tissue, lymphoma may show different appearances. Particularly, intra-osseous lesions 
with linear cortical signal abnormalities without substantial soft-tissue mass, or even normal-
appearing or thickened cortical bone without soft-tissue mass, may look non aggressive and 
even benign. In the present study no fewer than nine of 29 patients (31%) with PLB presented 
in that manner. Radiologists should thus be aware of that in the right clinical context. 
There are several limitations concerning this retrospec tive and largely descriptive study. The 
data obtained were collected from various institutions that had used different MR imaging 
systems, field strengths and protocols. In order to collect a larger number of patients, given 
the rarity of PLB, we could not avoid this. The assessment of hetero geneity or homogeneity 
of signal characteristics is quite subjective; however, for the goal of this study it was of 
minor importance. Fast dynamic contrast-enhanced sequen ces were used only incidentally. 
Nowadays, these acquisi tions are widely used to assess the biologic behavior of primary bone 
and soft-tissue tumors and to determine the response to chemo-and/or radiation therapy. 
With regard to PLB, the rapid decrease of tumor volume and the complete disappearance 
of the soft-tissue component on MR imaging has been described as a significant indicator of 
good response to treatment [24]. In this respect, MR imaging has a direct impact on individual 
patient care, which is however, outside the scope of this study. We could not determine how 
MR imaging had caused any change in clinical approach in the patients with PLB described 
here. Differentiating PLB from other malignant small round cell tumors, on the one hand, or 
reactive processes, on the other hand, based on (MR) imaging criteria only, is, in our opinion, 
not possible and not useful, which stresses the need for accurate core biopsy, which is definitely 
crucial for both diagnosis and staging purposes. 
Table 1. Relationship between MR imaging appearance of cortical bone and extension into the 
soft tissue in 29 patients with PLB 
Cortex appearance Extension into Extension into Extension into Total
 soft-tissue substantital soft-tissue limited soft-tissue absent
Normal 0 0 2 2
Permeative destruction 10 3 2 15
Focal disruption 2 0 0 2
Complete disruption 7 0 1 8
Cortex thickening 0 0 1 1
Tumor within cortex only 0 0 1 1
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Primary Lymphoma of Bone: 
Extranodal Lymphoma with Favourable Survival 
Independent of Germinal Centre, Post Germinal 
Centre, or Indeterminate Phenotype





Aims: To determine prognostic significance of immunohistochemical markers and investigate 
possible germinal centre (GC) derivation in primary lymphoma of bone (PLB).
Methods: In this study we have investigated the immunohistochemical expression of BCL-6, 
CD10, BCL-2, p53, CD30 and CD44 and MUM-1 in thirty-six patients with PLB. All cases 
were clinically staged and cases of secondary bone involvement of primary nodal lymphomas 
were excluded, prior to immunostaining. Clinical charts were reviewed for clinical symptoms 
and therapy given and survival post-biopsy was calculated. 
Results: All patients presented with pain and a palpable mass. The majority showed 
centroblastic-multilobated morphology, half of the cases (19/36) displayed a GC phenotype 
(CD10+BCL-6+ or CD10-BCL-6+MUM-1-), whereas 8/36 cases demonstrated a non-GC 
phenotype (CD10-BCL-6- or CD10-BCL-6+ MUM-1+). Nine cases were of indeterminate 
phenotype (CD10-BCL-6+; MUM-1 not available). Eight out of 22 evaluated patient samples 
showed immunoreactivity for MUM-1. Most patients (31/36) received combination therapy 
in the form of polychemotherapy and radiotherapy. The 5-year overall survival was 75%. No 
significant difference in survival was found between the three different tumour phenotypes, or 
for the tested antigens individually. Age at presentation and stage of disease were of significant 
influence on 5-year overall survival. Survival rates were 90% for the patients under 60 years of 
age and 40% for those of 60 years and older. Furthermore, survival rates were 90% for stage I 
vs. 41% for stage IV, respectively. 
Conclusion: This study illustrates the homogeneity of PLB. The majority of cases is of the GC 
phenotype and has a favourable prognosis.
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Introduction
Primary non-Hodgkin lymphoma of bone (PLB) is a rare neoplastic disorder, comprising 5% of 
extranodal lymphomas and less than 1% of all non-Hodgkin lymphomas.[1] It is an extranodal 
subtype of mostly diffuse large B cell lymphoma (DLBCL), which is a heterogeneous group of 
lymphomas. 
Studies on extranodal lymphomas are rare, even though the incidence of extranodal lymphoma 
in Western countries has increased in the last 40 years. 
Immunohistochemical studies on PLB are even rarer, likely because of the limited availability 
of tissue specimens of this disorder and technological difficulties in handling osseous tumour 
material.
PLB has morphological homogeneity and a relatively favourable clinical behaviour with a 
5-year overall survival of 90% for stage I disease, as published in our previous report.[2,3] 
In the last decade, insight into B-cell development and lymphoma pathogenesis has increased 
substantially due to the increasing availability of well-defined histogenetic markers. These 
include the expression of BCL-6 and CD10 protein, which are considered germinal centre (GC) 
markers, and of MUM1/IRF4, which denotes the final step of intra-GC B-cell differentiation, 
as well as subsequent steps of B-cell maturation towards plasma cells.[4] The expression of the 
anti-apoptotic factor BCL-2 and of the surface adhesion molecule CD44 is normally down-
regulated in GC B-cells.[5,6] Moreover, genotypic analyses have revealed several structural 
and numerical chromosomal changes in DLBCL, including translocations t(14;18)(q32;q21) 
and t(3;14)(q27;q32) that involve BCL-2 and BCL-6 genes, respectively. In numerous studies 
on DLBCL the effect of these chromosomal changes on prognosis has been debated, but a final 
conclusion cannot be drawn.[7-9]
Research in gene expression profiling has led to the concept that most DLBCL derive from GC 
B-cells or from their descendants, i.e. activated B-cells or non-GC B-cells.[10] Since most PLB 
have a centroblastic phenotype, it has been postulated that PLB represents a de novo DLBCL 
with a genetic relationship to GC B-cells.[11]
Recent studies have analyzed the expression of GC B-cell-associated antigens and other 
markers in PLB, showing that at least part of the patients with PLB have a GC signature, which 
was associated with a favourable clinical outcome.[7,11,12]
In the current study, immunohistochemical staining for BCL-6, CD10, BCL-2, MUM-1, p53, 
CD30 and CD44 was performed in 36 PLB patients to determine both possible GC origin of 





In this study we included the previously described cohort of patients combined with newly 
registered cases from 1995 until 2001.[2] This new cohort consisted of 83 cases. PLB was 
defined as a histologically proven non-Hodgkin lymphoma arising within the medullary cavity 
of a bone, with or without regional lymph node involvement, but without evidence of other 
extranodal involvement. Multiple bone lesions were acceptable as long as there was no evidence 
of earlier lymphoma involvement elsewhere. All cases selected were clinicopathologically 
reviewed independently by two pathologists, if needed with application of additional 
immunohistochemical stainings to confirm the diagnosis. Of the originally identified group 
of 106 patients 30 patients were excluded because of a different diagnosis after review of the 
histological slides, combined with new immunohistochemical data or clinical follow-up as 
described in our previous study. Clinical follow-up was updated. Adequate paraffin material 
for additional immunohistochemical studies was available in 36 cases, of which 14 cases were 
not described in our previous study.
Histological Classification and Immunohistochemistry (table 1)
The pathological diagnosis was established according to the WHO classification [13] using 
standard histological criteria and immunohistochemistry using antibodies directed against 
Vimentin, CD45, CD3, CD20, CD79a, and CD99. Immunohistochemical staining was 
performed on 4 µm sections of formalin-fixed, paraffin-embedded tissues, using standard 
procedures as detailed elsewhere.[2] In addition to the diagnostic marker panel listed above 
a set of markers relevant to a GC/non-GC phenotype or relevant to survival was used. The 
details of the antibodies are given in table 1.
Immunohistochemical Scoring
Two pathologists assessed all cases independently. Three categories were defined: negative, 30-
75% positivity or >75% positivity, reflecting the percentage of positive tumour cells. 
Statistical Methods
Survival curves were plotted following the Kaplan-Meier method and tested for statistical 
significance using the log-rank test. Overall survival (OS) was calculated from the date of 
diagnosis until death (all causes) or last-follow-up. The multivariate Wilson regression test 
was used to determine statistic significance of the parameters independent of the known IPI 
risk factors age and tumour stage. 
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Results
Clinical Features (table 2)
A group of 36 patients with PLB was studied. All the patients presented with pain and/or a 
palpable mass, most often at a single location in one of the long bones.
Multifocal bone involvement (scored as stage IV) was noted in 10 cases. Twelve out of all 36 
patients had undergone an incomplete staging procedure, according to the present standards. 
All stage IV patients had more than one bone localization and none had iliac crest bone 
marrow involvement. 
The male:female ratio was 26:10. The mean age at presentation was 48 years, ranging from 
18 years to 79 years. Clinical findings, including age, gender, primary location of tumour, 
treatment and outcome are summarized in table 2.
The IPI index could be calculated in 26 of the 36 cases. If unknown, this was mostly due to lacking 
laboratory results. The mean score was 2. The 5-year overall survival of this cohort was 75%. 
Most patients (31) received combination therapy in the form of poly-chemotherapy or surgical 
resection with radiotherapy. All chemotherapy courses were given with curative intentions. It 
consisted of cyclophosphamide, doxorubicin, vincristin, prednisone (CHOP) (16x), or CHOP-
like: cyclophosphamide, teniposide, doxorubicin, vincristin, bleomycin, prednisone (CHVmP/
BV) (8x) and prednisone, methotrexate, doxorubicin, cyclophosphamide, epipodophyllotoxin 
VP-16 (PROMACE) (5x).
Twenty-nine patients (80%) demonstrated a complete remission, including one spontaneous 
remission. The latter was reviewed on multiple occasions by different pathologists and 
haematologists, with the original diagnosis confirmed each time. To our knowledge this is the 
first case of PLB with a spontaneous remission mentioned in a study. Follow-up was available 
in all but one case. The median follow-up was 79 months. Four patients had progressive 
disease and died of disease. One patient had no change of disease and died during therapy. 
Table 1. Antibodies Used for Immunohistochemistry
Marker Clone Producer Type Isotype
BCL-2 124 Dako Mouse IgG1
BCL-6 PG-B6P Dako Mouse IgG-k
CD-3  Dako Rabbit Polyclonal
CD10 56C6 Neomarkers Mouse IgG1
CD20 L26 Dako Mouse IgG2a-k
CD30 BER-H2 Dako Mouse IgG1
CD44 156-3C11 Neomarkers Mouse IgG1-k
CD45 CLA Neomarkers Mouse IgG1-k
P53 DO-7 Neomarkers Mouse IgG2b-k
CD79a JCB117 Dako Mouse IgG1-k
CD99 O13 Zymed Mouse IgG1
MUM-1 MUM-1p Dako Mouse IgG1
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Table 2. Clinical Characteristics of the Patient Population Studied
Patient Sex Age Primary Multifocal Therapy  Result  Relapse 
   Location Disease
1 M 59 Clavicle  RT + SUR 4
2 F 61 Humerus  RT + SUR 4
3 M 50 Femur  RT + SUR 1
4 M 59 Femur IV RT + SUR 4
5 F 53 Femur  RT + SUR + 1
     CHOP-like
6 F 41 Femur  RT + CHOP 1
7 M 54 Scapula +   RT + SUR +  1
   Humerus  CHOP-like
8 M 23 Shoulder  RT + CHOP-like 1
9 M 28 Clavicle  RT + CHOP 1
10 M 69 Femur  RT + SUR + CHOP 1
11 M 18 Vertebral  RT + SUR +  1
   Column  CHOP-like
12 M 30 Femur IV Unknown 9
13 M 65 Humerus  RT + CHOP-like 1
14 F 38 Hipjoint IV None 1
15 M 40 Femur  CHOP 1
16 M 20 Femur  RT + CHOP 1
17 M 23 Femur  RT + SUR 1
18 F 18 Femur  RT + CHOP 1
19 M 61 Os Pelvis  RT + SUR +  9
     CHOP-like
20 M 30 Femur IV RT + CHOP 1 28 months
21 F 23 Scapula  RT + SUR +  1
     CHOP-like
22 M 31 Femur  RT + CHOP-like 1
23 M 72 Humerus  IV RT + CHOP 1
24 F 51 Vertebral IV RT + CHOP 1
   Column
25 M 58 Humerus  RT + CHOP-like 1
26 F 52 Os Pubis  RT + CHOP-like 1
27 M 27 Femur  RT + CHOP-like 1
28 M 79 Humerus IV RT + SUR + CHOP 4
29 M 46 Femur  RT + SUR + CHOP 1
30 M 51 Hipjoint  CHOP 1
31 F 78 Femur IV CHOP 1
32 F 71 Femur IV RT + SUR + CHOP 1
33 M 29 Humerus  RT + CHOP 1
34 M 72 Os Ileum  RT + CHOP-like 1
35 M 75 Femur IV SUR + CHOP 3
36 M 46 Humerus  RT + CHOP-like 1
1 Ann Arbor stage: Stage IV is Multifocal
2 RT: radiotherapy; SUR: surgery; CHOP and CHOP-like: chemotherapy
3 1: complete remission; 3: no change; 4: progressive disease; 9: no evaluation possible
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One patient experienced a nodal relapse at 28 months, with complete remission after second-
line chemotherapy and no evidence of disease at 118 months. 
There was a significant association between the IPI index factors age and stage of disease and 
survival. The overall 5-year survival for the patients under 60 years at the time of diagnosis 
Figure 1. Kaplan-Meier 
overall survival curve of age 
at diagnosis (p=0.0004)
A: survival % (in months) 
of patients of 60 years and 
younger
B: survival % (in months) 
of patients above 60 years 
of age
Figure 2. Kaplan-Meier 
overall survival curve of 
stage of disease (p=0.0085) 
A: survival % (in months) of 
stage I patients
B: survival % (in months) of 
stage IV patients 
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(n=26) was 90%, versus 40% for those patients who were over 60 years of age at the time of 
diagnosis (n=10; p-value=0.0004) (figure 1). The patients who presented with multiple bone 
lesions (n=10) at the time of diagnosis had a significantly worse survival than those who 
presented with a lymphoma at a single location (n=26), the overall 5-year survival being 41% 
versus 90%, respectively (p-value=0.0085) (figure 2). 
Table 3. Selection of Histological and Immunohistochemical Features
Patient Morphology CD10 BCL-6 MUM-1 Phenotype BCL-2 P53 CD30 CD44
1 Centro-multi - - - Non-GC - - - ++
2 Diff centro - + + Non-GC ++ ++ - ++
3 Diff centro + +  GC - + - ++
4 Diff centro - +  Indet + - - ++
5 Diff centro ++ ++  GC - - - -
6 Centro-multi ++ + - GC - - - +
7 Diff centro - +  Indet ++ - - ++
8 Centro-multi - +  Indet -  ++ -
9 Centro-multi - + - GC - - ++ -
10 Diff centro - - + Non-GC ++ + - ++
11 Centro-multi + ++  GC - + - +
12 Centro-multi - + - GC - + - +
13 Diff centro + - - GC - - ++ ++
14 Diff centro - +  Indet - + - +
15 Centro-multi - +  Indet - + - -
16 Diff centro - +  Indet - + - +
17 Centro-multi - -  Non-GC - + - ++
18 Diff centro + ++ + GC - + - ++
19 Centroblastic - + - GC -  - 
20 Immunobl - ++ + Non-GC ++ - - -
21 Centro-multi ++ ++ - GC - + - ++
22 Centro-multi - - - Non-GC - - - ++
23 Centro-multi ++ +  GC ++ + - ++
24 Centro-multi + -  GC ++ - - ++
25 Centro-multi - + - GC - - ++ ++
26 Centro-multi -   Indet ++ - - ++
27 Centro-multi - ++ - GC - + - 
28 Diff centro ++ + + GC ++ - ++ ++
29 Centroblastic - - + Non-GC ++ - - ++
30 Diff centro - ++  Indet ++ - ++ ++
31 Diff centro ++ + + GC - ++ - ++
32 Centro-multi - ++ - Indet - + ++ +
33 Centro-multi - + - GC - - - ++
34 Centro-multi - + + Non-GC - ++ - ++
35 Centro-multi ++ + - GC ++ - - +
36 Centro-multi + ++ - GC  - - ++
-: no staining
+: 30 to 75% of the tumour cells positive staining
++: more than 75% of the tumour cells positive staining
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Histological and Immunohistochemical Features (table 3)
The histological and immunohistochemical findings are summarized in table 3. Although 
not recognized anymore as separate tumour entities in the present WHO, a morphological 
subclassification was performed in order to establish whether a specific morphology was 
apparent. Twenty cases demonstrated centroblastic-multilobated morphology, 13 cases showed 
centroblastic mono- or polymorphic morphology, two cases showed centroblastic-centrocytic 
morphology and one case demonstrated immunoblastic morphology. No prognostic significant 
difference in survival between the morphological tumour subtypes was found, nor did we find 
a difference in morphological subtype between the stage I and IV patients. 
Nuclear expression of BCL-6 was seen in 28 cases. BCL-2 expression was demonstrated in 
12 cases, 8 cases showed both BCL-2 and BCL-6 expression. CD10 expression was seen in 
13 cases. MUM-1 expression was found in 8 out of 22 cases which could be evaluated. P53 
expression was found in 16 cases. CD30 expression was seen in 7 cases, CD44 expression was 
seen in 29 cases. 
Applying the Hans’ algorithm, GC phenotype was defined as CD10+BCL-6+, non-GC phenotype 
was defined as CD10-BCL-6-. In case of CD10-BCL-6+, MUM-1 expression was determined.
[14] If MUM-1 was negative, the phenotype was defined as GC, if MUM-1 expression was 
positive, the case was defined as non-GC. If MUM-1 expression was unavailable, the phenotype 
was defined as indeterminate. Nineteen out of 36 patients revealed a GC phenotype. Tumours 
that were negative for both CD10 and BCL-6, the non-GC phenotype, were seen in 8 cases. 
The phenotype was defined as indeterminate in 9 cases.
There was no significant difference in survival between the different tumour phenotypes. 
None of the other antigens tested had a significant association with survival.
Discussion
Our study of PLB investigated immunohistochemical expression of BCL-6, CD10, BCL-2, 
MUM-1, p53, CD30 and CD44 to analyse the prognostic significance of these markers and to 
determine GC derivation.
Patients displayed homogeneous clinical features, consistent with the few other reports on 
PLB in literature, but not earlier was the homogeneity as strong as in the present cohort.
[2,12,15-19]
Similar to other series the presenting symptom in all patients was pain, usually combined 
with a palpable mass; the site of presentation was mostly in the long bones and the age at 
presentation was in the fifth decade. The histology was consistently compatible with DLBCL 
and displayed predominantly a centroblastic morphology with multilobated nuclei. 
The PLB patients had a good prognosis, with a complete remission rate of 80% and an overall 
survival of 75%. Only one patient suffered a relapse, which was followed by complete remission. 
Our series included 10 cases of stage IV disease with multiple bone localizations, with a 
5-year overall survival of 41%, whereas most prior studies excluded patients with multiple 
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bone involvement, which leads to an imperfect representation of the spectrum of this 
disease.
Two IPI risk factors, age at presentation and stage of disease, were of significant influence on 
5-year overall survival, with a survival rate of 90% for the patients under 60, and 40% for those 
of 60 years and older. Survival rates were 90% for stage I vs 41% for stage IV, respectively. 
In recent studies, the relationship of B-cell malignancies to normal stages of B-cell differentiation 
and activation has been partly clarified using genomic scale gene expression profiling. These 
molecular distinctions between subgroups of DLBCL are important because a difference in 
response to multi-agent chemotherapy is noted between these subgroups, with a favourable 
outcome for the GC phenotype. The Hans’ algorithm is the most widely accepted algorithm 
to define phenotype using immunohistochemistry. Previous studies on PLB confirmed the 
positive effect on survival for the GC phenotype, whereas a worse survival in case of lack of 
CD10 expression, presence of MUM-1 expression and non-GC phenotype was found.[11,12]
The p53 tumour suppressor gene product is expressed in 20 to 50% of DLBCL. Protein 
expression in DLBCL is associated with treatment failure and poor outcome. In this study 
p53 expression was found in 16 of 36 cases, without a significant effect on survival.[20] The 
intrinsic capacity of CD44+ tumour cells to disseminate does not appear to play a role in PLB, 
as all positive cases were localized to the bone without evidence of extra-osseous involvement 
and without an adverse effect on prognosis. 
In our study we could not demonstrate a statistically significant influence on prognosis of 
tumour phenotype, nor did we find a significant effect on prognosis by the individual 
immunohistochemical markers. We think this difference between our results and those of 
others is explained partly by the favourable survival of our cohort, with only five tumour related 
deaths and only one relapse out of 36 patients. Another difference between our cohort and that 
of others is the striking homogeneity, with very similar morphology, phenotype and clinical 
Figure 3. A typical case of 
primary lymphoma of bone 
showing centroblastic cells 
with nuclear multilobated 
features.  
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course for the majority of the cases. This positive and homogeneous clinical course results 
in few statistical events. Remarkably however, 50% of the patients with progressive disease 
had a non-GC phenotype. Furthermore, the one patient with a relapse had an immunoblastic 
morphology and was of the non-GC phenotype. In a previous study, a similar negative 
correlation with survival was noted for the immunoblastic phenotype.[2] 
Of note, all recent PLB studies found a clear morphologic and phenotypic relation of PLB 
to GC cells, despite the fact that normal bone or bone marrow lacks germinal centres. 
These findings support the hypothesis that PLB represents a de novo DLBCL with a genetic 
relationship to GC like lymphomas. Some authors speculate that there are specific homing 
factors for these tumour cells. More research is necessary to investigate the pathophysiology 
of this rare extranodal subtype of DLBCL. 
In conclusion, this study illustrates the homogeneity of PLB. The majority of cases is of the GC 
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Array-based comparative genomic 
hybridisation analysis reveals recurrent 
chromosomal alterations in primary 
diffuse large B cell lymphoma of bone





Aims: Primary non-Hodgkin’s lymphoma of bone (PLB) is a rare subtype of primary extranodal 
diffuse large B cell lymphoma. PLB has morphological homogeneity and a relatively favourable 
clinical behaviour. Recent studies report that array-based comparative genomic hybridisation 
(array-CGH) analysis can be used to classify lymphomas into clinically and biologically 
relevant phenotypes and possibly reveal differences in oncogenic mechanisms. Here the 
authors performed the first array-CGH study to detect illness related genomic alterations in 
nine, clinically well-staged primary lymphoma of bone cases.
Methods: Nine frozen samples from primary lymphoma of bone patients were 
immunophenotyped and subsequently investigated using a well-established array-CGH 
platform. The array-CGH results were confirmed by fluorescence in situ hybridisation. Clinical 
data and follow-up were obtained for all nine patients. 
Results: Of the nine patients, eight reached complete remission, and one had progressive 
disease and died of primary lymphoma of bone. Frequent aberrations were: loss of 14q32 
(n=7), trisomy 7 (n=6), gain of the long arm of chromosome 1 (n=5) and amplification of 
2p16.1 (n=4). No statistically significant correlation between genetic abnormalities and clinical 
outcome was found.
Conclusions: The authors found several recurrent genomic aberrations, including five 
cases with gain of 1q and four cases with 2p16.1 amplification. These findings are associated 
with a germinal centre-like phenotype and favourable treatment outcome, and differ from 
chromosomal aberrations found in other extranodal lymphomas. These findings further 
substantiate the notion that primary lymphoma of bone should be considered as a distinct 
entity not only on clinic-pathological grounds but also on the genomic level as well.
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Introduction
Primary non-Hodgkin’s lymphoma of bone (PLB) is a rare neoplastic disorder, comprising 
5% of extranodal non-Hodgkin’s lymphomas (NHLs).1 It is a subtype of primary extranodal 
diffuse large B cell lymphoma (DLBCL), which, as a whole, is the most heterogeneous group 
of lymphomas. PLB as an entity, however, has morphological and clinical homogeneity.2 
Characteristically, these lymphomas present in the long bones such as the humerus or the 
femur with pain or a palpable mass. During MR imaging, it might not present infrequently 
as a non-aggressive lesion.3 Complete remission is usually achieved with a combination of 
chemotherapy and radiotherapy, with only a few patients relapsing during follow-up. Needless 
to say, adequate staging including a CT-scan of the thorax and abdomen, and iliac crest bone 
marrow biopsy are essential in order to rule out disseminated DLBCL involving the bone 
instead of a primary bone presentation.
Studies on extranodal lymphoma are infrequent, even though the incidence of extranodal 
lymphoma in Western countries has increased in the last 40 years.4 5 This discrepancy can be 
explained by the low frequency of primary involvement of any particular extranodal site. To 
overcome these small patient numbers, many authors have combined all extranodal cases to 
obtain enough statistical power for their research. However, it is questionable whether such 
a general distinction has any clinical relevance, since clinical outcome and tumour biology 
differ substantially between the various extranodal localisations.6-8 Studies on PLB specifically 
are even rarer because, apart from the low patient numbers, the research on PLB is hindered 
due to limited availability of frozen tissue specimens and technological difficulties related to 
handling the tumour material of osseous origin. 
Research in gene-expression profiling has led to the concept that most DLBCLs derive from 
germinal centre (GC) B cells or from their descendants, that is activated B cells or non-GC B 
cells. Recent studies have shown that the majority of PLBs are of the GC-like phenotype which 
is associated with a better prognosis than the non-GC phenotype.2 9 10 Array-based comparative 
genomic hybridisation (array-CGH) enables us to detect the genomic copy number of 
alterations of cancers with high resolution. Recent studies report that this technique can be 
used to classify lymphomas into the clinically and biologically relevant phenotypes, GC-like 
and non-GC-like, and possibly reveal differences in oncogenic mechanisms.11
No studies using array-CGH analysis on PLB have been published so far. We investigated 
genomic alterations in nine well-documented cases of PLB using this technique and analysed 
the results in the context of data available from literature on studies of other distinct subtypes 




Tissue sample collection and selection
Ten frozen samples from PLB patients were collected from the tissue bank at the Leiden University 
Medical Center, and one sample was collected from the tissue bank at the University Medical 
Center Groningen, The Netherlands. Following quality control of DNA, we disregarded two 
samples and performed an array-CGH analysis on nine of the 11 cases. All samples were handled 
in a coded fashion, and all procedures were performed according to the ethical guidelines, ‘Code 
for Proper Secondary Use of Human Tissue in The Netherlands’ (Dutch Federation of Medical 
Scientific Societies). Clinical data and follow-up were obtained on all nine patients. PLB was 
defined as a histologically proven non-Hodgkin’s lymphoma arising within the medullary cavity 
of a bone, with or without regional lymph mode involvement, but without evidence of other 
extranodal involvement.1 Multiple bone lesions were acceptable as long there was no evidence of 
earlier lymphoma elsewhere. All patients were staged adequately with an MRI of the tumour site, 
CT-scan of the thorax and abdomen, and iliac crest bone marrow biopsy. The relevant clinical 
and follow-up data for the patients investigated are summarised in table 1.
Histological classification and immunohistochemistry
The pathological diagnosis was established according to the WHO classification14 using standard 
histological criteria and immunohistochemistry using antibodies directed against Vimentin, 
CD45, CD3, CD20, CD79a and CD99. Immunohistochemical staining was performed on 
4 mm sections of formalin-fixed, paraffin-embedded tissues, using standard procedures as 
detailed elsewhere.2 In addition to the diagnostic marker panel listed above, a set of markers 
relevant to a GC/non-GC phenotype was used: CD10, BCL6 and MUM-1.
Table 1. Overview of the clinicopathological data and test results. 
patient gender age stage Localisation treatment result Follow-up
L2734 m 46 I Humerus CHOP-like +RT CR Disease-free
L2735 m 58 I Humerus CHOP-like+RT CR Disease-free
L2736 m 61 IV Os ilium/ CHOP-like+RT PR Dead from 
    vertebra    disease
L2737 m 25 I Femur R-CHOP CR Disease-free
L2738 f 72 I Femur R-CHOP+RT CR Disease-free
L2739 f 32 I Femur CHOP-like+RT CR Disease-free
L2740 m 33 I Tibia CHOP-like+RT CR Disease-free
L2385 m 25 I Tibia R-CHOP + RT CR Disease-free
L2060 m 35 I Scapula CHOP + RT CR Disease-free
CR, complete remission; F female; M, male; PR, progressive diseas; RT, radiotherapy; Stage, 
Ann Arbor stage (Stage IV is multifocal),
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Array-CGH 
Genomic DNA was isolated using high salt after SDS/proteinase K digestion; 500 ng was 
labelled with Cy3-dCTP (GE Healthcare, Diegem, Belgium) using the BioPrime DNA Labelling 
System (Invitrogen, Breda, The Netherlands). As a reference DNA, 500 ng of either male or 
female human genomic DNA (Promega, Leiden, The Netherlands) was labelled using Cy5-
dCTP. Labelled samples were hybridised array slides containing ~3500 BACs clones spaced 
at ~1 Mb density over the full genome, a set of subtelomeric sequences for each chromosome 
arm and a few hundred probes selected for their involvement in oncogenesis, and were 
meticulously validated.15 As all clones were part of the Human Genome Project, updated 
sequencing information is available from the ENSEMBL web page (http://www.ensembl.org). 
The clones were grown, amplified and spotted as described previously, and made available by 
the Wellcome Trust Sanger Institute (http://www.sanger.ac.uk). The array slides were produced 
in-house at Leiden University Medical Center according to Knijnenburg et al.16 
Hybridisation and posthybridisation washing steps were performed on a HS400 TECAN 
automated hybridisation station (Tecan, Giessen, The Netherlands) according to Knijnenburg 
et al,17 and slides were then scanned with a GenePix Personal 4100A scanner at 5 mm resolution 
(Axon Instruments, Union City, California). The spot intensities were measured using GenePix 
Pro 4.1 software. With this software, spots in which the reference DNA intensity was below five 
times the mean of the background or presented more than 3% saturated pixels were excluded 
from further analysis. The test/reference ratios were normalised for the median of the ratios 
of all features. The triplicates of the features were averaged in a homemade routine developed 
in Microsoft Excel 2000, and spots outside the 20% CI of the average of the triplicate were 
excluded. Only those targets presenting at least two spots within 20% CI of their average were 
used. Any imbalances in the targets were determined based on log2 ratios of the average of 
their replicates, and we considered sequences as amplified or deleted when outside the ±0.3 
range.
Resulting data files were further analysed, and log2 ratio values were analysed using R packages 
CGHCall and VAMP webtool.18 19 Hemi- and homozygous loss were defined as one and two 
levels lower than normal respectively, and gain as one or two levels higher than normal. 
Gains with more than two levels were identified as amplified regions. Genomic locations 
(chromosome band and clone positions) were determined according to Ensembl Gene build 
(database version 54.36p) (http://www.ensembl.org/Homo_sapiens).
Confirmatory interphase fluorescence in situ hybridisation (FISH) on formalin 
fixed paraffin embedded tissue (FFPE) samples 
To confirm the array-CGH results, we performed interphase FISH on 4 µm thick FFPE tissue 
of the L2736 with small amplified regions of chromosomes 2p16.1 containing the BCL11A 
and REL gene loci. A panel of BAC probes was selected covering the region, and as a reference 
chromosome two centromer specific alphoid repet probes were combined. The following BAC 
probes were used: RP11-416L21, RP11-498O5, RP11-493E12, RP11-373L24 and RP11-440P5 
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(the latter two were present on the BAC array-CGH platform detecting the amplification) 
for the alphoid repeat sequence D2Z2 plasmid clone. Probes were labelled using standard 
protocols as described earlier.20 21
Interphase FISH experiments was performed according to previously described protocols on 
formalin-fixed paraffinembedded tissue slides.22 Slides were embedded in Citifluor antifading 
solution containing with 4’,6-diamino-2-phenylindole-dihydrochloride (DAPI)/citifluor 
(500 ng/ml) (Brunschwig Chemie, Amsterdam, The Netherlands). Image acquisition was 
performed using a DM-RA epifluorescence microscope (Leica Microsystems b.v. Rijswijk, 
The Netherlands) equipped with a Quantix camera (Roper Scientific, Fairfield, Iowa). Grey 
scale images were collected with a 63T oil immersion objective by using appropriate filters to 
visualise the FITC, Cy3 and DAPI stainings. For further image processing, in-house-developed 
software (ColourProc) was used.23
Results
All patients presented with pain and/or a palpable mass, most often at a single location in one 
of the long bones. Multifocal bone involvement, scored as stage IV, was noted in one case, 
and none had iliac crest bone marrow involvement. The male:female ratio was 7:2. The mean 
age at presentation was 43, ranging from 25 years to 72 years. Clinical findings, including age, 
gender, primary location of tumour, treatment and outcome, are summarised in table 1. The 
minimum follow-up was 12 months. All patients were treated with CHOP (cyclophosphamide, 
doxorubicin, vincristin, prednisone) or CHOP-like chemotherapy; three were also treated 
with rituximab. Eight patients were also treated with involved field radiotherapy. Of the nine 
patients, eight reached complete remission; one had progressive disease within 3 months after 
completing R-CHOP and died of disease, after an initial response to chemotherapy.
Immunohistochemical features
Applying Hans’ algorithm, the GC phenotype was defined as CD10+BCL-6+, and the non-GC 
phenotype was defined as CD10-BCL-6–. In the case of CD10-BCL-6+, the phenotype was 
defined as GC if MUM-1 expression was negative and as non-GC if MUM-1 was positive.24 
Eight cases were of the GC phenotype, and one case was of the non-GC phenotype. The results 
are summarised in table 2.
Array-based CGH
Following quality control, frozen tumour biopsy samples of nine patients diagnosed as having 
PLB were analysed for copy-number alterations using array-CGH. The array-CGH profiles 
showed numerous chromosomal alterations in all analysed PLB samples. No common alteration 
was observed in all cases. The overall gain/loss frequency was plotted using an R script, CGHC 
all (figure 1A). The overall pattern of chromosomal alterations of PLB is characterised by gains 
of large genomic regions on chromosome 1q, 6p and 7, and losses of regions on chromosome 
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1p, 6q and 15. A high level of amplification was observed involving the 2p15–16.1 region in 
4/9 cases (table 2). None of the analysed samples presented homozygous deletions. In order 
to delineate the smallest recurrent chromosomal regions with altered probes common to the 
set of array-CGH profiles in at least 35% of the analysed cases, we determined the minimal 
common regions (MRC) containing potentially relevant genes25 and the VAMP web tool.26 An 
overview of the MCRs is given in table 3. Eight MCRs were identified, and four of the eight 
regions were full chromosome or full chromosome arms (gain: 1q, 6q and chromosome 7, loss: 
chromosome 15). The four MCRs with smaller genomic changes were: loss of chromosome 
1p36.3e1p35.1 (w30 Mb region), high level of amplification of chromosome 2p16.1e2p15 (0.9 
Mb), gain of chromosome 6p21.31 (3.7 Mb) and loss of 14q32.33 (1 Mb). Analysis of the co-
occurrence frequency of the genomic alteration revealed that the deletion of 1p, 6q and 14q 
and the monosomy of chromosome 15 were mostly together, while no such similar association 
was seen for other regions. Clustering of the analysed samples, due to the low numbers of 
samples and homogeneous clinical group, were not informative. 
Next, we matched the four MCRs with the Cancer Gene Census, a list of genes for which 
mutations have been casually identified in cancer.27 In table 3B, the four identified MCRs with 
the 12 identified tumour suppressor genes and oncogenes are presented. The most highly 
recurrent MCR with loss of the IGH gene may represent a clonal immunoglobulin gene 
rearrangement rather than direct oncogenic involvement.
Confirmatory interphase FISH
For two cases (L2735 and L2736) with small amplification of the 2p16.1 region containing the 
BCL11A and REL gene loci, 4 µm FFPE sections were cut and analysed by interphase FISH. A 
probe mixture was used containing five BAC clones covering the amplified region - including 
those two that were present on the BAC array and showed the amplification (RP11-373L24 
and RP11-440P5)- labeled in red and mixed with a chromosome 2 specific alphoid repeat probe 
labeled in green. As a control, an FFPE section from skin was used and showed a distinct pattern 
Table 2. Overview of Hans’ algorithm and selected array-based comparative genomic 
hybridisation results
Patient CD10 BCL-6 MUM-1 phenotype Gain of 1q Amplification of  
      2p16.1
L2734 - + - GC + -
L2735 - + - GC + +
L2736 + + - GC - +
L2737 - + - GC - +
L2738 - - + Non-GC - -
L2739 + + - GC + -
L2740 + + - GC + -
L2385 - + - GC + +
L2060 - + - GC - -
GC, germinal-centre-like phenotype; Non-GC, non-germinal-centre-like phenotype.
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of two centromeric signals in green with two 2p16.1 locus-specific signals in red (figure 1C 
left panel). The FISH showed a clear amplification pattern in case L2736 with a high level of 
amplification involving the 2p16.1 locus mingled with normal cells (figure 1C right panel; white 
arrows indicate the normal cells, and the red arrow points to a tumour cell with amplified red 
signals).
Correlation with clinical data
Because of the very good clinical outcome of this group of patients, which results in few 
statistical events, no statistically significant correlation between genetic abnormalities and 
prognosis could be made. The one patient with a dismal clinical course showed no specific 
array-CGH pattern. It did have the 2p16.1 amplification, but not a gain of 1q. The clinical 
Table 3. Array-based comparative genomic hybridisation result overview in PLB
(A) Most recurrent chromosomal alterations in PBL (losses and gains are separated) 
Chromosome Start End Start End Size (bp) CNA No of
Band Clone Clone Position Position   cases
   (bp) (bp)
1p36.3- RP4- RP1- 3214521 33379650 30165129 Loss 5
1p35.1 785P20 117N3
6q14.1-6q27 RP11- RP5- 83405494 170509779 87104285 Loss 4
 25O6 1086L22
14q32.33 RP11- CTC- 105267358 106278173 1010815 Loss 7
 417P24 820M16
15q11.2-.5 RP11- RP11- 20363717 100036184 79672467 Loss 5
15q26  289D12 14C10
1q21.1- RP3- RP11- 142642781 247249719 104606938 Gain 5
1q44.1 365I19 438H8
2p16.1- RP11- RP11- 60501800 61422449 920349 Amplification 4
2p15 440P5 479F13
6p21.31 RP11- RP1- 33521322 37077773 3556451 Gain 4
 175A4 90K10
7p22-7q36.2 RP11- RP11- 885103 157752947 156867844 Gain 6
 449P15 518I12
B: Candidate genes residing in frequently altered regions
Chromosome Chromosome Size (bp) CNA No of  Cancer 
 Band   cases Gene 
     Census
1 1p36.3-1p35.1 30165129 Loss 5 LCK, MDS2, SDHB,
      PRDM16, PAX7
14 14q32.33 1010815 Loss 7 IGH
     
2 2p16.1-2p15 920349 Amplification 4 REL, BCL11A
6 6p21.31 3556451 Gain  4 HMGA1, SFRS3, 
     FANCE 
CNA, copy number alteration.
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Figure 1. Overview of the array-based comparative genomic hybridisation (array-CGH) results and 
confirmatory fluorescence in situ hybridisation (FISH) experiments. (A) Array-CGH cumulative 
summary plot of all analysed PLB samples generated by default settings of the CGHCall R software. 
Probabilities for genomic losses displayed on the left y axis and gain probabilities are on the right 
y axis. The calculated probabilities for genomic loss or gain are represented by red and blue lines, 
respectively. (B) Representative array-CGH profile of case L2385. Normalised log2 ratios are plot-
ted with the scale on the right axis. Vertical bars indicate loss and gain probabilities. The probabi-
lity scale is on the left axis; reversed (‘1–’) for the gains. Segments are plotted as horizontal lines. 
Segments with a bar extending beyond the middle axis (probability >0.5) are called gains or losses. 
Amplification locations are indicated by tick marks on the top axis. This case shows loss of 1p, gain 
of 1q, amplification of 2p15e16.1 (see blue tick mark on the top), gain of chromosome 7 and loss of 
chromosome 15 without involvement of chromosome 6. (C) Interphase FISH results using 2p16.1 
locus-specific pore set (red) and chromosome 2 centromer-specific alphoid repeat sequence probe 
(green) in combination with DNA counterstaining agent: DAPI (blue). Left panel: two normal cells 
with two green and two red signals as indicated by white arrowheads. Right panel: interphase FISH 
proved the amplification of the 2p16.1 locus in case L2736. The red arrowhead indicates amplified 




parameters were unfavourable, with age at presentation over 60, multifocal disease and bulky 
tumour load. The one case with a non-GC phenotype did show an excellent response to 
chemotherapy. There was no specific array-CGH pattern in this non-GC phenotype either.
Discussion
Here we present the first array-CGH study on PLB. The sample size of the cohort was restricted 
due to the rarity of this tumour and, more specifically, the scarcity of fresh frozen tumour 
samples of PLB. As a result, few studies on PLB have been published because of these difficulties, 
which stresses the importance of the current investigation. We and others demonstrated 
in previous reports, using clinical and immunohistochemical data, that PLB has a favourable 
prognosis and is of GC-like origin in the majority of cases.2 10 28 Our current cohort is 
representative of the typical clinical spectrum of PLB, with the majority of the tumours 
presenting in the long bones, and all but one patient achieving complete remission. 
Most prior studies on PLB excluded patients with multiple bone involvementd stage 
IV patients–which leads to an imperfect representation of the spectrum of this disease. 
The patient with progressive disease was the only patient in this cohort with multifocal 
disease. Moreover, his age at presentation was over 60. As we previously reported, these two 
parameters, both included in the IPI risk index, are the main adverse clinical prognostic factors 
in PLB.2 29 
DLBCL is the most heterogeneous group of lymphomas. Over the years, various subtypes 
and classifications have been designed in an attempt to predict clinical course and prognosis 
for individual patients. Historically, DLBCL is divided into nodal and extranodal lymphoma. 
The data currently available in the literature on extranodal lymphoma are often obtained 
from studies performed on extranodal lymphoma in general. However, since clinical outcome 
varies substantially among all the specific sites of primary lymphoma, this generalisation 
might be clinically inappropriate. It is therefore important to study any particular primary 
site of lymphoma as a separate entity. Research in genomic scale gene-expression profiling has 
resulted in the definition of two tumour phenotypes in DLBCL, one GC-like, and one non-GC-
like. A difference in response to multiagent chemotherapy is noted between these subgroups, 
with a favourable outcome for the GC phenotype. Unfortunately, these two phenotypes still 
show considerable clinical and morphological heterogeneity. 
Recent studies show that array-CGH can be used for identifying these tumour phenotypes 
in malignant lymphoma as well.11 More importantly, array-CGH can identify chromosomal 
aberrations within the same tumour phenotype, which is a subsequent step in making the 
group of (extranodal) DLBCL less heterogeneous.
For example, primary cutaneous large B cell lymphoma, leg-type, which has an moderately 
aggressive course, frequently shows a 9p21.3 deletion.13 The prognosis of immune privileged 
associated DLBCL, such as testis and CNS DLBCL, is only slightly better. The typical aberration 
of these immune privileged lymphomas is deletion of 6q21e22.12 Both subtypes of extranodal 
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lymphoma are mostly of the non-GC origin, but differ considerably in clinical outcome. The 
dissimilar array CGH results between these subtypes of extranodal DLBCL suggest another 
tumour aetiology via different oncogenic mechanisms. 
In this study, we found several recurrent aberrations, all of which have been described in 
DLBCL before. Intriguingly, several of these chromosomal changes are described in the 
literature as negative prognostic factors, which cannot be confirmed in this study focusing on 
PLB specifically. The data from our and other previous studies11-13 suggest that for extranodal 
DLBCL, genotype-based classification (ie, array-CGH study) in combination with the site of 
involvement is a better class identifier. Loss of 14q32.33 was the most frequently observed event 
(seven cases). This deletion indicates a breakpoint in the IGH locus, which has been frequently 
described in B cell malignancies and, more specifically, in extranodal cutaneous DLBCL, such 
as large B cell lymphoma of the leg, and in primary cutaneous follicle centre lymphoma.30 
Trisomy 7 (six cases) is associated in the literature with progression of follicular lymphoma 
and with DLBCL, mostly as an adverse prognostic factor.31 2p16.1 amplification (four cases) 
and gain of 1q (five cases) have been associated with GC phenotype in the literature.8 32 33 
Our array-CGH results and immunohistochemical results confirm the previously described 
GC-like origin of PLB and are in accordance with its favourable prognosis (table 2). Of note, 
the one patient with non-GC phenotype did not have a gain of 1q or 2p16.1 amplification. It 
has been suggested that the REL proto-oncogene is the target gene of 2p16.1 amplification in 
DLBCL.34 It encodes a transcription factor in the nuclear factor (NF) kappa-B family. Studies 
on the prognostic influence of 2p16.1 amplification in DLBCL are still controversial.35 The one 
case in this study with 2p16.1 amplification, age over 60 at presentation, stage IV at presentation 
and an unfavourable outcome together with the favourable outcome of the case with non-GC 
phenotype, which had stage I at presentation, does suggest that clinical parameters in PLB have 
a strong influence on prognosis. Gain of the short arm of chromosome 6 and loss of the long 
arm of chromosome 6 are both adverse prognostic factors frequently found in DLBCL.12 36 In the 
future, array-CGH could be helpful in risk-stratification of extranodal DLBCL patients, which 
are all treated in a similar way at this moment. The goal would be to select those patients who 
need more intensive therapy than the standard regime of R-CHOP and radiotherapy on the 
one hand, and to protect the patients with a more favourable prognosis against too intensive a 
treatment on the other hand.
Conclusions
We found several recurrent genomic aberrations, including five cases with gain of 1q and four 
cases with 2p16.1 amplification, which are both associated with the GC phenotype. These 
findings concur with the relatively good prognosis of this rare type of extranodal lymphoma 
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Primary lymphoma of bone is a rare type of extranodal diffuse large B-cell lymphoma with a 
relatively favorable outcome. Recent scientific interest has focused on elucidating the role of 
nuclear factor-κB pathway in lymphomagenesis and its possible value as a therapeutic target. 
In nodal B-cell non Hodgkin lymphomas, constitutive activation of nuclear factor-κB appears 
to be especially involved in tumor cell survival in the non-germinal center type of diffuse 
large B-cell lymphoma. In nuclear factor-κB activation, two major pathways are involved: 
the classical and the alternative pathway. We here investigate nuclear factor-κB activation via 
both pathways in primary lymphoma of bone, performing immunohistochemical staining 
procedures for nuclear factor-κB family members on tumor tissues of 50 cases. Nine cases 
(18%) showed nuclear positivity for p50, and one case showed nuclear co-expression of 
p52. Positivity for p50 was not restricted to either germinal center- or non-germinal center 
phenotype of the tumor, or related to an inferior prognosis or treatment resistance. P65 did 
not show significant nuclear expression. The immunohistochemical nuclear expression of 
p50 in 18% of the cases suggests constitutive activation of nuclear factor-κB via the classical 
pathway in a minority of primary lymphoma of bone patients. In contrast to other extranodal 
types of diffuse large B-cell lymphoma, there was a lack of nuclear co-expression of p65, which 
may suggest different pathway activation. Alternative pathway activation of nuclear factor-
κB does not appear to be significantly involved, as only one case showed significant nuclear 
expression for p52. Finally, nuclear expression of p50 was not preferentially detected in non-
germinal center type or germinal center type primary lymphoma of bone, or related to an 
inferior prognosis. Therefore, in contrast to nodal diffuse large B-cell lymphoma, the nuclear 
factor-κB pathway does not appear to be an attractive pathway for targeted therapy in primary 
lymphoma of bone.
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Introduction
Primary non Hodgkin lymphoma of bone (PLB) is a rare neoplastic disorder, comprising 5% 
of extranodal lymphomas(1) and less than 2% of all non Hodgkin lymphomas.(2) PLB mainly 
presents as an extranodal subtype of diffuse large B cell lymphoma (DLBCL) and shows a 
non-aggressive radiological presentation.(3) Although extranodal DLBCL in general seems to 
represent a biologically very heterogeneous group of lymphomas with a varying prognosis, 
PLB shows morphological and clinical homogeneity with a relatively favorable clinical 
outcome. The 5-year overall survival rate is approximately 90%. (4;5) Complete remission is 
usually achieved with combined chemotherapy and radiotherapy regimens. PLB exhibits a 
germinal center B-cell (GCB) phenotype in at least half of the cases, but still a considerable 
amount of tumors show a non germinal center (GC)/activated B-cell (ABC) phenotype.(6) Age 
at presentation over 60 years and immunoblastic tumor cell morphology/non GC phenotype 
are considered the most important unfavorable predictive factors, although results concerning 
the prognostic value of the GC phenotype cannot be reproduced in all studies on PLB.(5;7-9) 
The most frequently encountered genomic aberrations include gain of 1q, amplification of 
2p16.1 and loss of 14q32.33.(10) Considering the amplification of 2p16.1 in PLB, encoding for 
nuclear factor (NF)-κB family member c-Rel, we were interested in elucidating a potential role 
of constitutive activation of NF-κB in the pathogenesis of PLB.
NF-κB is a transcription factor involved in several cellular survival mechanisms. It has been 
implicated that NF-κB activity plays a role in the pathogenesis of different types of B-cell 
lymphomas, especially in nodal non-GC/ABC type DLBCL, although it is also encountered 
in a minority of GCB type DLBCL.(11) Constitutive activation of NF-κB is required for survival 
of activated ABC type DLBCL cells in vitro(12) and ABC type DLBCLs preferentially express 
known NF-κB target genes.(13) Furthermore, mutations in multiple genes involved in the NF-
κB activation pathway can cause deregulation of NF-κB in DLBCL.(11) It is shown that a small 
molecule inhibitor of IκB kinase, an essential molecule in the activation of NF-κB, is selectively 
toxic to ABC type DLBCL cell lines.(14) These results suggest a role for the NF-κB pathway as a 
potential therapeutic target in DLBCL. 
In this study, 50 cases of PLB were selected and examined for immunohistochemical expression 
of three NF-κB subunits (p65, p50 and p52) as surrogate read-outs for constitutive activation 
of the canonical pathway (p65 and p50) and alternative pathway (p52) of NF-κB. We evaluated 
the expression of NF-κB proteins in relation to the postulated cell of origin (GC versus non-





Fifty cases of primary lymphoma of bone were investigated, 27 were collected at the 
Leiden University Medical Center (Leiden, The Netherlands) and 23 at the Semmelweis 
University (Budapest, Hungary). According to the WHO classification(1) PLB was defined 
as a histologically proven non Hodgkin lymphoma arising within the medullary cavity of a 
bone, with or without regional lymph node involvement, but without evidence of other 
extranodal involvement, or as non Hodgkin lymphoma with multiple bone involvement 
without lymph node or visceral involvement. Staging procedures included Computed 
Tomography scan, iliac crest bone marrow biopsy and total blood count. The pathological 
diagnosis was established according to the WHO classification (15) using standard histological 
criteria and immunohistochemical staining procedures. All cases selected were reviewed 
independently by at least two pathologists. The samples were handled in a coded fashion, 
and all procedures were performed according to the ethical guidelines, ‘Code for Proper 
Secondary Use of Human Tissue in The Netherlands’ (Dutch Federation of Medical Scientific 
Societies).
Tissue microarray
Tissue microarrays were prepared using hematoxylin and eosin (H&E) stained sections from 
each paraffin-embedded, formalin-fixed block to select tumor rich areas. Accordingly, 3 
representative 2-3 mm cores were obtained from each case and inserted in a grid pattern into a 
recipient paraffin block using a tissue arrayer device (TMA Master, 3D Histech Ltd, Budapest, 
Hungary).
Antibodies and Immunohistochemistry
Immunohistochemical staining was performed on 4 μm paraffin sections using standard 
procedures. After antigen retrieval by boiling for 10 minutes in 10 mmol/L citrate buffer (pH 6.0, 
tissue sections were incubated overnight with p50 (dilution 1:200, Abcam, Cambridge, UK), p52 
(18D10) (dilution 1:100, Cell Signaling Technology, Beverly, MA, USA) and p65 (dilution 1:200, 
Neomarkers, Fremont, CA, USA). Sections were then incubated for 30 minutes with PowerVision 
Poly-horseradish peroxidase. Subsequently, a 10-minute incubation with diaminobenzidine 
(DAB) solution (Sigma-Aldrich, Zwijndrecht, The Netherlands) was performed. Finally, all 
slides were counterstained with Mayer’s haematoxylin. Immunohistochemical stainings for 
BCL6, CD10 and IRF4/MUM1 were performed as previously described.(6)
Immunohistochemical Scoring
NF-κB expression was detected as nuclear and/or cytoplasmic staining of tumor cells for p50, 
p52 and/or p65. Nuclear staining was scored according to the estimated percentage of positive 
tumor cells; less than 10%, 10-20%, 20-30% or more than 30%, irrespective of cytoplasmic 
staining. In the largest cohort of DLBCL published thus far(10), cases were considered to be 
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positive for NF-κB activity when ≥30% of tumor cells showed nuclear staining. In our series, 
cases showed either virtually no nuclear staining (<10%, merely scattered positive tumor cells), 
or staining of 20% or more for p50 and p52. Because of this dichotomy, we considered cases 
of more than 20% positive tumor cells positive for nuclear staining. Tonsil sections were used 
as positive controls. As an extrinsic control group, paraffin sections of cases of nodal DLBCL 
and primary central nervous system DLBCL were also stained, since these groups have been 




Patient characteristics are summarized in Table 1, subdivided by GC or non-GC phenotype 
as defined by diagnostically performed immunohistochemical staining procedures for CD10, 
BCL-6 and IRF4/MUM1, according to the Hans’ algorithm. All stage IV patients had multifocal 
osseous disease without lymph node or visceral involvement. Forty-three patients received 
mulitagent chemotherapy, of which 9 were additionally treated with rituximab.
NF-κB expression
Nuclear immunohistochemical expression of p50 was detected in 9 cases (18%, see Figure 
1), whereas almost all other cases just showed cytoplasmic expression throughout the tumor 
tissue. Nuclear expression of p50 was equally distributed between the GC- and non-GC type 
of PLB as determined by Hans’ algorithm (see Table 2). 
P52 showed nuclear expression of 20-30% of tumor cells in only one case. This case was a 
non-GC type PLB, and also showed nuclear p50 positivity in more than 30% of tumor cells. 
After a follow-up of ten years, this patient was still alive without recurrence of disease after 
polychemotherapy treatment. 
Staining procedures for p65 did not show significant nuclear staining. Only scattered cells 
were considered positive (scored as less than 10% nuclear staining), while cytoplasmic staining 
in virtually all tumor cells was detected in 46 and 43 cases respectively. 
None of the nuclear p50 positive cases presented with a recurrence or progression of disease, 
although for one of the positive cases, no follow-up data were available. Furthermore, exploring 
known prognostic factors in PLB, p50 positivity was evenly distributed between patients under 
and over 60 years of age and was not related to disease stage at time of presentation. 
Discussion
The NF-κB comprises of a family of transcription factors that control genes that play critical 
roles in B-cell activation, proliferation and resistance to apoptosis. The NF-κB family has five 
members: p65 (RelA), p50 (NF-κB1), p52 (NF-κB2), RelB and c-Rel. In unstimulated human 
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Table 1: Patient characteristics.
 all GC-type non-GC-type
 50 25 25
Sex
  male 32 16 16
  female 18 9 9
Age (years)
  mean 49 50 47
  range 18-78 18-78 20-72
Location
  femur 25 11 14
  humerus 6 5 1
  os ileum 6 3 3
  vertebra 5 3 2
  other 8 3 5
Stage
  I 33 17 16
  II 4 0 4
  III 0 0 0
  IV 11 8 3
  unknown 2 0 2
Treatment
  PCT + RT 25 13 12
  PCT + RT 14 5 9
  RT + resection 6 4 2
  PCT + RT + resection 3 1 2
  PCT + resection 1 1 0
  unknown 1 1 0
Outcome
  complete response 37 19 18
  partial response 3 0 3
  progressive disease 7 4 3
  unknown 3 2 1
Recurrence
  yes 2 1 1
  no 45 22 23
  unknown 3 2 1
Status
  A- 37 19 18
  A+ 0 0 0
  D- 1 0 1
  D+ 9 4 5
  unknown 3 2 1
Follow-up (months)
  mean 57 52 62
  range 0-240 0-192 0-240
GC-type: germinal center phenotype, non-GC-type: non germinal center phenotype, PCT: 
polychemotherapy, RT: radiotherapy, A-: alive without evidence of disease, A+: alive with evidence 
of disease, D-: died of causes unrelated to disease, D+: died of causes related to disease
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Figure 1: Immunohistochemical staining of nuclear factor-κB pathway members.
The majority of cases of primary lymphoma of bone merely showed cytoplasmic staining of the 
tumor cells for p50 (a) and p52 (c). P65 was only detected in the cytoplasm of tumor cells (e), while 
p50 and p52 showed nuclear staining in part of the tumor cells (b,d). P65 was not detected in the 
nucleus of tumor cells in primary lymphoma of bone (e). However, cases of primary central nervous 




cells, these NF-κB proteins and their precursor proteins reside in the cytoplasm in an inactive 
form bound to NF-κB inhibitory proteins (IκBs). The NF-κB pathway signals downstream 
after activation through different kinds of surface receptors, including the B-cell receptor. Two 
major signaling pathways account for the activation of NF-κB. In the canonical pathway, signal 
transduction events lead to activation of the IκB kinase complex resulting in phosphorylation 
and proteasomal degradation of IκB. Heterodimers and homodimers of p50, p65 and c-Rel can 
then be translocated to the nucleus to regulate gene transcription. The alternative pathway 
is characterized by IκB kinase complex activation through NF-κB induced kinase, eventually 
leading to processing of the p52 precursor subunit into active p52 translocating to the nucleus 
and forming a heterodimeric complex with RelB.(17;18) The clinical importance of the two 
different pathways of activation includes the potential of targeted therapy directed against NF-
κB activation, as some specific inhibitors only target one of both activation pathways. (19)
This is the first study reporting on NF-κB activation in PLB. In our cohort, 18% of cases 
demonstrated nuclear positivity for p50, suggesting constitutive activation of the classical NF-
κB pathway in a minority of PLB. Only one case showed significant nuclear positivity for p52, 
which implies that constitutive activation of NF-κB through the alternative pathway may not 
play a significant role in PLB. This is in contrast to previous reports showing nuclear staining 
for p52 in one-third (ABC-type) to one-fifth (GCB-type) of cases of nodal DLBCL.(11) We could 
not demonstrate co-localization of p65 with p50 in the nucleus, which is in line with recent 
results in nodal DLBCLs (20). Interestingly, nuclear immunohistochemical staining for p65 was 
observed in primary central nervous system DLBCL and primary cutaneous DLBCL, two 
other variants of extranodal DLBCL.(16;21) It would be interesting to investigate whether the 
lack of nuclear staining for p65 indicates that another form of constitutive activation of NF-κB 
is involved in PLB, possibly by forming p50 homodimers in the nucleus or by co-localizing 
with C-Rel.
A considerable amount of nodal DLBCLs are known to show constitutive activation of NF-κB. 
In non-GC DLBCLs, gene set enrichment analysis showed high NF- B transcriptional activity 
in >95% of cases, whereas this percentage was 47% in GC DLBCL. Immunohistochemical 
staining procedures in the same group showed nuclear localization of p50 and/or p52 in 61% 
and 30%, respectively.(11) Although this difference might be interpreted as a result of lower 
Table 2: Nuclear immunohistochemical positivity for p50. 
 All GC-type non-GC-type
<10% 41 21 20
10-20% 0 0 0
20-30% 2 0 2
>30% 7 4 3
GC-type: germinal center type, non-GC-type: non germinal center type.
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sensitivity of immunohistochemical staining to detect aberrant NF-κB activity, it may also 
reflect the inability of gene set enrichment analysis to discriminate signals deriving from 
infiltrating reactive cells. Indeed, in our series, small infiltrating T-lymphocytes did also show 
nuclear staining for some of the NF-κB family members. Therefore, it seems reasonable to 
assume that immunohistochemistry may be a surrogate marker for determining constitutive 
activation of NF-κB. 
Although constitutive activation of NF-κB in nodal DLBCL was not restricted to the non-
GC type, a marked preference for non-GC tumors was observed (11). In our cohort, nuclear 
expression of p50 was not confined to the tumors with a non-GC phenotype and was evenly 
distributed between GC- and non-GC like tumors. Activation of the NF-κB pathway as shown 
by upregulated gene expression of different NF-κB target genes is even considered as a specific 
gene array signature of the ABC/non-GC type DLBCL (12). It therefore seems remarkable that 
in our series only 20% of non-GC type PLBs showed nuclear p50 staining. These results once 
more emphasize the heterogeneity of nodal and extranodal DLBCLs and of the different types 
of extranodal lymphomas.
It is hypothesized that NF-κB activation plays a role in chemotherapy resistance and a 
subsequent poor outcome in different types of lymphomas, by promoting cell proliferation, 
blocking apoptosis and potentially blocking differentiation and promoting metastases.(22;23) As 
PLB generally has an excellent prognosis, relating nuclear p50 staining to survival may not be 
relevant. Nevertheless, in our cohort, all patients with nuclear positivity for p50 are still alive 
without disease. This implies that p50 positivity in PLB is not a negative prognostic factor, 
and that constitutive activation of NF-κB is not likely to be significantly involved in (chemo)
therapy-resistance in the minority of PLB cases that show progressive disease.
In conclusion, our results show that NF-κB activation through the classical pathway is seen 
in a minority of cases of PLB and is evenly distributed among cases with a non-GC or GC 
phenotype. Therefore, in contrast to nodal DLBCL, the NF-κB pathway does not appear to be 
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SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Since Oberling first mentioned primary lymphoma of bone in 1928 as a distinct entity, 
knowledge on lymphoma in general has increased substantially. The improvements in diagnosis 
and treatment of primary diffuse large B lymphoma of bone in over eighty years has changed 
treatment from amputation of an extremity to combined chemo- and radiotherapy. The earlier 
treatment of amputation usually resulted in complete remission, but with a high treatment 
related morbidity.
Primary diffuse large B cell lymphoma of bone however has remained somewhat of an outcast 
in lymphoma literature and in clinical practice. The incidence is low, although with the 
establishment of immunohistochemical markers for monoclonal B-cells the entity has become 
easier to recognize. Currently there is the suggestion that the frequency of occurrence might 
have been underestimated in the past. While the diagnostic improvements have helped the 
patient, ironically it has had an adverse effect on research, since less tumor material is sent to 
referral hospitals or registries such as the Netherlands Committee on Bone Tumors for advice. 
In general hospitals extranodal lymphoma of any particular site is not always documented as 
such, which makes it more difficult to find adequate patient numbers for research purposes. 
Moreover, there are often technical difficulties in handling the osseous tumor material, which 
hampers scientific research as well. This most likely explains the few studies on primary diffuse 
large B cell lymphoma of bone in literature, with often small patient numbers and poorly 
compatible cohorts. By definition, primary lymphoma of bone excludes secondary bone 
localization of nodal lymphoma, but when a patient presents with stage IV primary lymphoma 
of bone at different skeletal sites, it can be difficult to exclude primary nodal disease. For this 
reason, stage IV patients are often excluded in primary lymphoma of bone studies, causing 
an incomplete representation of the clinical spectrum. Although clinical stage is defined as 
a negative prognostic factor, the stage four cases often do reach complete remission. It was 
therefore important to us to include all tumor stages in our study cohorts.
This thesis describes the first extensive multidisciplinary study on primary diffuse large B cell 
lymphoma of bone with large patient numbers, including our cohort of 60 cases in chapter two. 
When studied in large numbers, it is noticeable how homogeneous the clinico-pathological 
presentation of primary diffuse large B cell lymphoma of bone in fact is. The tumor presents 
in either the femur or the humerus in over 50% of the cases, the stage of the disease is most 
often stage I with pain usually as the presenting symptom. The clinical outcome following 
therapy including chemotherapy and irradiation is complete remission in most cases, with a 
low incidence of recurrent disease. Morphologically, the tumor most frequently consists of 
large centroblastic cells with either multilobated features or mono-/polymorphic features, 
although some cases with an immunoblastic tumor cell phenotype are also encountered. The 
treatment schedules varied in this cohort, from surgery and radiotherapy to CHOP multi-agent 
chemotherapy and radiotherapy. The 5 year overall survival in our series for the whole cohort 
was 61%. No significant difference was found between the different treatment schedules, as 
long as a combination of radiotherapy and chemotherapy was given. We demonstrated that the 
IPI risk factors age at presentation and stage of disease have a negative influence on prognosis 
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in primary lymphoma of bone. We did not find a significant impact on prognosis of tumor 
localization, which is opposite earlier reported findings. We found a trend towards worse 
survival for the immunoblastic tumor subtype, as it was called at that time, as compared to the 
centroblastic mono-/polymorphic or multilobated tumor subtype according to the updated 
Kiel classification. 
Of note, as we describe in chapter three, the clinico-pathological homogeneity is in 
contradiction with the radiological characteristics of the disease. We discovered that the MRI 
image of primary diffuse large B cell lymphoma of bone can be rather deceptive. We studied 
the MRI characteristics of 29 bone lymphoma patients. We found that the MRI features are 
not uniform at all. The majority of the patients displayed a combination of definite cortical 
abnormalities and extension to the soft tissue, but up to 31% of the patients showed MRI 
features that looked radiologically non-aggressive or even benign. The study stresses the 
need for accurate core biopsy to establish a definite diagnosis of primary diffuse large B cell 
lymphoma of bone, following adequate local imaging including MRI.
We have used various techniques to identify parameters for risk stratification in primary 
diffuse large B cell lymphoma of bone patients. In chapter four, we determined the prognostic 
significance of several immunohistochemical markers: BCL-6, CD10, MUM1, BCL-2, p53, 
CD30 and CD44. We also investigated the possible germinal center derivation of primary 
diffuse large B cell lymphoma of bone. Applying the Hans’ algorithm, which is an algorithm 
using immunohistochemical staining results for BCL-6, CD10 and MUM1 to determine the 
germinal center B-cell subtype of diffuse large B-cell lymphoma versus the non-germinal 
center B-cell subtype, we concluded that 19 out of a cohort of 36 cases displayed a germinal 
center-like phenotype. Eight of 36 cases demonstrated a non-germinal center-like phenotype, 
whereas nine of 36 cases were of indeterminate phenotype. No significant difference in survival 
was found between the different tumor phenotypes, nor for the tested immunohistochemical 
markers individually. We did find again a statistically significant influence on prognosis of the 
IPI risk factors age at presentation and stage of disease. This confirmed our findings from our 
earlier study (chapter two), although this might be partially explained by the fact that some 
patients were included in both study cohorts.
In chapter five, we described the first array-CGH study of primary diffuse large B cell 
lymphoma of bone, in which we investigated genomic alterations in nine such cases. We 
found several recurrent genomic aberrations, but none had statistically significant prognostic 
influence. The most frequent finding was five cases with gain of 1q (five out of nine cases) and 
2p16.1 amplification (four out of nine cases). The amplificated region 2p16.1 encodes for the 
proto-oncogene REL, a transcription factor of the NF-κB family.
In chapter six we described the first study on NF-κB pathway activation in primary diffuse 
large B cell lymphoma of bone. This signaling pathway is known to have a role in tumorigenesis 
in lymphoma; recent research has focused on elucidating its working mechanisms through 
the classical pathway and the alternative pathway and on its possible role in targeted therapy. 
We investigated 50 cases for involvement of aberrant NF-κB activation by performing 
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immunohistochemical stainings for different NF-κB family members and evaluated its possible 
prognostic influence. In a minority (19%) of cases, we found substantial nuclear staining of 
p50, as an indication of aberrant activation of the classical pathway of NF-κB activation, while 
alternative activation did not appear to be significantly involved. The nuclear expression of 
p50 was not preferentially detected in non-germinal center or germinal center type cases, nor 
related to an inferior prognosis.
The knowledge of this rare type of extranodal non-Hodgkin lymphoma has increased by 
describing the complete clinicopathological spectrum of primary diffuse large B cell lymphoma 
of bone, including clinical characteristics, radiological aspects and molecular genetic factors. 
When we studied this disease in a large number of patients it became clear that primary diffuse 
large B cell lymphoma of bone is a homogeneous entity with a favorable outcome, contrary 
to what was earlier believed for extranodal lymphoma in general and primary diffuse large B 
cell lymphoma of bone in particular. We have demonstrated that primary diffuse large B cell 
lymphoma of bone is often of germinal center cell derivation, but the associated favorable 
outcome was also seen in cases with characteristics of the non-germinal center phenotype. 
Interestingly, in our first study we did find a worse outcome for the so-called immunoblastic 
tumor subtype, which largely corresponds to the non-germinal center phenotype. In later 
studies we could not confirm this trend. We could not identify any statistically significant 
molecular-biological prognostic parameters. We think this is explained partly by the favorable 
survival of our cohort, with very similar morphology, phenotype and clinical course for the 
majority of the cases. This positive and homogeneous clinical course results in few statistical 
events. 
The pathogenesis of primary diffuse large B cell lymphoma of bone is unknown. Most cases 
probably arise de novo without a recognizable initial noxe; more specifically there is no 
relationship with a history of osteomyelitis or fracture. Of note, of all the prognostic parameters 
that we studied, the clinical parameters, especially the IPI risk factors age at presentation and 
stage of disease, have the strongest influence on prognosis. 
We hope that this thesis on primary diffuse large B cell lymphoma of bone, a rare and fascinating 
subtype of extranodal lymphoma, will ultimately help to improve the treatment of diffuse large 







Primair bot lymfoom is een zeldzame aandoening. Het is een extranodaal subtype van het 
grootcellig B non Hodgkin lymfoom, dat zich meestal presenteert in de lymfeklieren (nodale 
subtype). De eerste keer dat deze ziekte als aparte entiteit werd erkend in de wetenschappelijke 
literatuur was in 1928, maar het duurde nog tot 1963 voordat de term bot lymfoom officieel 
erkend en gebruikt werd. Dat dit zo lang duurde heeft verschillende oorzaken. Ten eerste is een 
primair bot lymfoom zeldzaam. Zoals al eerder is gezegd komt een lymfoom meestal voor in 
de lymfeklieren, en als het zich al in de botten presenteert, dan is het meestal een secundaire 
localisatie van een lymfoom dat zich oorspronkelijk in de lymfeklieren manifesteerde. Ten 
tweede is de diagnostiek van een bot lymfoom niet eenvoudig. Er kan makkelijk verwarring 
ontstaan met bijvoorbeeld een sarcoom of juist een benigne aandoening zoals een bot infectie. 
Pas sinds de komst van moderne, gestandaardiseerde diagnostische technieken, zoals de 
immunohistochemie sinds 1987, kan in moeilijke gevallen de diagnose toch met zekerheid 
gesteld worden.
Nederlandse Commissie van Beentumoren
In 1953 werd de Nederlandse Commissie van Beentumoren opgericht in Leiden. Dit is een 
groot nationaal archief waarin alle maligne bottumoren in Nederland worden geregistreerd. 
Inmiddels bevat het archief meer dan 25.000 casus, alle inclusief klinische gegevens bij 
presentatie, follow-up, radiologie en histologische coupes. Dit archief bood de unieke kans 
om een groot cohort van primair bot lymfoom patienten samen te stellen; op dit moment is 
ons cohort een van de grootste wereldwijd. De opbouw van dit cohort was het startpunt van 
dit onderzoek.
Klinisch-pathologische kenmerken
Primair bot lymfoom komt het meeste voor in de lange pijpbeenderen, het meest frequent in 
het bovenbeen of de bovenarm. De gemiddelde leeftijd bij presentatie is in de vijfde decade. 
De ziekte komt vaker bij mannen voor dan bij vrouwen, in een ratio van 1.8 : 1. Morfologisch 
hebben de tumoren grote centroblast-achtige cellen met multilobulaire kenmerken. De 
morfologische classificatie wordt vaak bemoeilijkt door mechanische schade aan het biopt, 
ontkalkingsprocedures en relatief weinig tumor cellen in het biopt. 
De behandeling bestaat tegenwoordig uit R-CHOP chemokuren, vaak nog gevolgd door 
bestraling. Vroeger, tot eind jaren zeventig, werd in het algemeen het aangedane lichaamsdeel 
geamputeerd. De prognose voor botlymfoom patienten is in het algemeen gunstig, met een 
vijfjaars overleving van 75% voor de gehele groep, en meer dan 90% voor stadium I patienten.
Risicostratificatie in diffuus grootcellig B Non Hodgkin lymfoom
Diffuus grootcellig B Non Hodgkin lymfoom is een zeer heterogene groep van tumoren met 
sterk uiteen lopende ziektebeelden en prognoses. Er zijn reeds vele onderzoeken gedaan om 
binnen deze groep risicoclassificatie systemen te ontwerpen en prognostische indicatoren 
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te definieren om patienten te identificeren die zwaardere behandeling nodig zullen hebben 
dan het standaard regime van R-CHOP.  Een van de eerste risicoclassificatie systemen was 
de internationale prognostische index, IPI genoemd. Deze index werd ontworpen in 1993, en 
deelt de patienten in op grond van een score voor de klinische parameters leeftijd, conditie, 
LDH waarde in het bloed, aantal aangedane extranodale klieren en ziekte stadium. Deze index 
werkt goed voor nodale lymfomen, maar veel minder voor extranodale subtypes. 
Een modernere manier om non Hodgkin lymfoom patienten in te delen in prognostische 
subgroepen maakt gebruik van de moleculair genetische kenmerken van de tumorcellen. 
Met behulp van gen-expressie profilering worden twee tumor types onderscheiden: het 
kiemcentrum fenotype en het zogenaamde “ geactiveerde B cell”  type. Het laatste tumortype 
heeft een slechtere prognose, onafhankelijk van klinische parameters. Tegenwoordig is het 
mogelijk om met een eenvoudiger techniek, dat wil zeggen imuunhistochemie op paraffine 
coupes, toch deze indeling te maken. Dat maakt het mogelijk om deze risicoclassificatie ook te 
gebruiken in een algemeen ziekenhuis zonder speciale onderzoeksfaciliteiten. 
Met meer verfijnde technieken, die wel alleen in onderzoeks context worden gebruikt op dit 
moment, zoals array-based comparative genomic hybridization analysis wordt op dit moment 
gezocht naar aanvullende prognostische parameters. Alhoewel er verschillende kandidaat 
parameters zijn, is deze risicoclassificatie nog onvoldoende uitgekristalliseerd om op brede 
schaal al toe te kunnen passen.
In hoofdstuk twee hebben we de tumormorfologie en het klinische beloop van 60 patienten 
bestudeerd, waarbij we hebben gezocht naar prognostisch significante factoren voor dit lymfoom 
type. We hebben onder andere tumorsubtype, wijze van behandeling en de parameters van de 
internationale prognostische index getest op hun waarde bij het primaire bot lymfoom. Tumor 
subtype en leeftijd bij presentatie bleken het meest significant van invloed op de prognose bij 
deze groep patienten.
In hoofdstuk drie hebben we de MRI karakteristieken van 29 bot lymfoom patienten 
onderzocht. De wetenschappelijke literatuur over dit onderwerp is schaars en niet eenduidig. In 
tegenstelling tot wat eerdere studies concluderen hebben wij geen uniform MRI beeld kunnen 
vaststellen. Ook bij MRI diagnostiek is het moeilijk om een botlymfoom te onderscheiden van 
een andere maligne bottumor of van een botontsteking. Het blijft dus uitermate belangrijk 
om in een dergelijke situatie een biopsie van het afwijkende bot gedeelte te nemen. Om geen 
storing van het radiologische beeld door de biopsie te veroorzaken dient de biopsie na de 
radiologische documentatie, inclusief de MRI plaats te vinden.
In hoofdstuk vier hebben we diverse immuunhistochemische markers onderzocht en hun 
associatie van expressie op de prognose van primair bot lymfoom patienten vastgesteld. Door 
technische moeilijkheden met het kalkhoudende materiaal van botlymfomen was dit type 
onderzoek eerder nog maar weinig gedaan. In ons onderzoek hebben we geen individuele 
markers gevonden die een significante invloed hebben op de prognose van primair bot 
lymfoom. Met behulp van het zogenaamde Hans’ algorithme, een methode om het tumor 
fenotype door middel van drie immuunhistochemische markers vast te stellen, hebben we 
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gevonden dat ongeveer vijftig procent van de patienten een kiemcentrum fenotype heeft, een 
type met een meestal gunstige prognose.
In hoofdstuk vijf hebben we de eerste array-CGH studie op bot lymfomen in de 
wetenschappelijke literatuur beschreven. We hebben met behulp van deze techniek 9 tumoren 
onderzocht op het aantal genoom veranderingen dat daarin voorkomt. Ons resultaat was dat 
er bij deze bot tumoren meerdere genoom veranderingen te vinden zijn die ook al in andere 
lymfoom types zijn beschreven. Deze veranderingen worden meestal geassocieerd met een 
gunstige prognose, maar ook hierin is de literatuur niet eenduidig. Ook met deze techniek is 
weer een indeling naar tumor fenotype mogelijk. Wij konden in dit kleine cohort onze eerdere 
bevinding dat meer dan vijftig procent van het kiemcentrum fenotype is, bevestigen. Wij 
hebben echter geen statistisch significant effect op prognose kunnen vinden.
In hoofdstuk zes hebben we NF-κB activatie in primair bot lymfoom beschreven. NF-κB speelt 
een belangrijke rol in cel proliferatie en regulatie van apoptose. Bovendien wordt steeds meer 
bekend over de rol van NF-κB in het ontstaan van maligne lymfomen. NF-κB activatie verloopt 
via twee verschillende mechanismes, de klassieke weg en de alternatieve weg. De klassieke 
activatie weg wordt vaker gevonden in tumoren van het kiemcentrum fenotype. De alternatieve 
activatie weg wordt meer beschreven in tumoren van het geactiveerde B cell fenotype en is 
geassocieerd met een ongunstige prognose. Wij hebben in onze studie uitsluitend activatie van 
de klassieke weg gevonden. Interessant genoeg was de activatie niet beperkt tot tumoren van 
het kiemcentrum fenotype in ons cohort. Wij hebben geen negatieve invloed op de prognose 
gevonden.
Conclusies
Primair bot lymfoom is een zeldaam subtype van diffuus grootcellig B non Hodgkin lymfoom. 
De klinische presentatie en de histologische morfologie is zeer homogeen, echter de 
radiologische presentatie is divers. Over het algemeen is het ziektebeloop gunstig, met een 
vijf jaars overleving van stadium I patienten van meer dan 90%. Van de tot nu toe bekende 
prognostische parameters bij grootcellig B non Hodgkin lymfoom hebben leeftijd bij presentatie 
en stadium van de ziekte een statistisch significante invloed bij primair botlymfoom. Van het 
tumor fenotype, in meerderheid kiemcentrum fenotype, en genomische aberraties hebben we 
geen statistisch significante invloed aan kunnen tonen. 
Deze studie van een zeldzaam type extranodaal lymfoom heeft een bijdrage proberen te leveren 
aan het ontrafelen van de heterogene groep van ziekten die onder de noemer diffuus grootcellig 
B non Hodgkin lymfoom wordt geschaard. Door onderzoek naar de verschillende subtypes 
van deze grote groep lymfomen zal uiteindelijk duidelijk worden welke gemeenschappelijke 
pathofysiologische mechanismen deze groep binden en welke mechanismen subtype specifiek 
zijn. Een beter begrip van het ontstaan van grootcellig B lymfomen zal uiteindelijk leiden tot 
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